



04/10/00

## DNAX RESEARCH INSTITUTE

901 California Avenue  
Palo Alto, CA 94304-1104ASSISTANT COMMISSIONER FOR PATENTS  
BOX PATENT APPLICATION  
Washington, D. C. 20231

Honorable Sir:

Transmitted herewith for filing under 37 CFR 1.53(b) is the:  
[ ] patent application, [ ] continuation patent  
application, [X] divisional patent application of:**MAMMALIAN CELL SURFACE ANTIGENS;  
RELATED REAGENTS****Inventors: Daniel M. Gorman, Troy D. Randall and Albert Zlotnik**1. PRIORITY -- 35 U.S.C. 119

- [X] This application claims priority from each of the following Application Nos./filing dates:  
This application is a divisional application of copending 08/911,423, filed August 14, 1997,  
(issue fee mailed December 28, 1999), which claims benefit from provisional applications  
60/023,419, filed August 16, 1996, and 60/027,901, filed October 7, 1996.

2. RELATE BACK -- 35 U.S.C. 120

- [X] Please amend the specification on page 1, line 4 by deleting [This filing is] and replacing with  
--This application is a divisional of commonly assigned, copending application 08/911,423,  
filed August 14, 1997, which is --

3. ENCLOSED ARE:

- [X] Patent Application Cover Sheet, 1 page (unnumbered);  
[X] Specification, 62 pages (1-62);  
[X] Sequence Listing, 10 pages (63-72);  
[X] 22 Claims, 4 pages (73-76);  
[X] Abstract, 1 page (77);  
[ ] --0-- sheet(s) of [ ] formal [ ] informal drawing(s);  
[X] Declaration and Power of Attorney, (3 pages), which is a copy from previous application, under  
37CFR 1.63(d), with Explanation/Cover Letter (1 page), (mailed on January 28, 1998, in  
connection with 08/911,423, as part of the response to Notice to File Missing Parts - Filing Date  
Granted);  
[X] Sequence Submission and Amendment (26 pages), which is a copy from previous application, under  
37CFR 1.821(e), with Explanation/Cover Letter (2 pages), (mailed on January 28, 1998, as part of the  
Response to Notice to File Missing Parts - Filing Date Granted, in connection with 08/911,423);  
[X] please refer to parent application for computer readable sequence listing, or  
[ ] with a new copy of the diskette recorded on \_\_\_\_\_;  
[ ] Preliminary Amendment;  
[ ] Petition to Extend Time for two months;  
[X] Return postcard.

4. MISCELLANEOUS

- [ ] A petition to extend time to respond in the above-identified prior application is enclosed.  
[ ] Please enter the enclosed preliminary amendment.  
[ ] Please cancel claim(s) \_\_\_\_\_.  
[ ] Other: Applicants respectfully request the same Restriction Requirement as issued on May 11, 1998,  
(Paper No. 7), in the parent application, U.S.S.N. 08/911,423.

"Express Mail" Label No.: EL 367 648 299 US

Date of Deposit: April 10, 2000

Atty. Docket No.: DX0612K1BI hereby certify that this is being deposited with the United  
States Postal Service "Express Mail Post Office to  
Addressee" service under 37 CFR 1.10 on the date  
indicated above and is addressed to the Box: Patent  
Application, Assistant Commissioner for Patents,  
Washington, D.C. 20231.

By

Lois E. Miller

April 10, 2000



5. FEE CALCULATION (37 CFR 1.16)

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
FOR:	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	22 -20=	2 *
INDEP CLAIMS	3 -3 =	0*
[ ] MULTIPLE DEPENDENT CLAIM PRESENTED		
* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.		

Other Than a Small Entity

RATE	FEE
	\$ 690.00
x 18=	\$ 36.00
x 78=	\$ 0.00
+270=	\$ 0.00
TOTAL	\$726.00

Please charge DNAX Deposit Account No. 04-1239 as follows:

- ☒ Filing fee  
☒ Any additional fees associated with this paper or during the pendency of this application  
☐ Extension Fees \_\_\_\_\_ (A petition for a \_\_\_\_\_-month extension is enclosed)

**Total** (filing, claim and extension fees): \$726.00

Two copies of this sheet are enclosed.

Date: April 7, 2000

Respectfully submitted,  
 DNAX RESEARCH INSTITUTE

Edwin P. Ching  
 Edwin P. Ching  
 Reg. No. 34,090

DNAX Research Institute  
 901 California Avenue  
 Palo Alto, CA 94304-1104  
 Telephone (650) 852-9196  
 Facsimile (650) 496-1200

Inventors:

Troy D. Randall, a citizen of the United States,  
residing at 100 Algonquin Avenue, P.O. Box 59;  
Saranac Lake, New York 12983; and

EM161836055US

Date of Deposit is August 14, 1997

Lois E. Miller August 14, 1997  
Lois E. Miller date

Schering Corporation, a New Jersey Corporation

EL367648299US

DXOG12K1B

April 10, 2000

## MAMMALIAN CELL SURFACE ANTIGENS; RELATED REAGENTS

The present filing is a conversion from  
5 U.S. Provisional Patent Applications 60/023,419, filed  
August 16, 1996 and 60/027,901, filed October 7, 1996, to a  
U.S. Utility Patent Application.

## FIELD OF THE INVENTION

10 The present invention generally pertains to molecules  
that control activation and expansion of mammalian cells,  
especially mammalian immune system cells. The invention  
provides purified genes, proteins, antibodies, and related  
15 reagents useful, for example, to regulate activation,  
development, differentiation, and function of various cell  
types, including hematopoietic cells. In particular, the  
invention provides mammalian 312C2 genes, gene products,  
compositions, and methods for using these.

## 20 BACKGROUND OF THE INVENTION

The activation of resting T cells is critical to most  
immune responses and allows these cells to exert their  
regulatory or effector capabilities. See Paul (ed; 1993)  
Fundamental Immunology 3d ed., Raven Press, N.Y. Increased  
25 adhesion between T cells and antigen presenting cells (APC)  
or other forms of primary stimuli, e.g., immobilized  
monoclonal antibodies (mAb), can potentiate the T-cell  
receptor signals. T-cell activation and T cell expansion  
depends upon engagement of the T-cell receptor (TCR) and  
30 co-stimulatory signals provided by accessory cells. See,  
e.g., Jenkins and Johnson (1993) Curr. Opin. Immunol.  
5:361-367; Bierer and Hahn (1993) Semin. Immunol. 5:249-  
261; June, et al. (1990) Immunol. Today 11:211-216; and  
Jenkins (1994) Immunity 1:443-446. A major, and well-  
35 studied, co-stimulatory interaction for T cells involves  
either CD28 or CTLA-4 on T cells with either B7 or B70  
(Jenkins (1994) Immunity 1:443-446). Recent studies on



CD28 deficient mice (Shahinian, et al. (1993) Science 261:609-612; Green, et al. (1994) Immunity 1:501-508) and CTLA-4 immunoglobulin expressing transgenic mice (Ronchese, et al. (1994) J. Exp. Med. 179:809-817) have revealed

5 deficiencies in some T-cell responses though these mice have normal primary immune responses and normal CTL responses to lymphocytic choriomeningitis virus and vesicular stomatitis virus. As a result, both these studies conclude that other co-stimulatory molecules must  
10 be supporting T-cell function. However, identification of these molecules which mediate distinct costimulatory signals has been difficult.

The inability to modulate activation signals prevents control of inappropriate developmental or physiological  
15 responses in the immune system. The present invention provides at least one alternative costimulatory molecule, agonists and antagonists of which will be useful in modulating a plethora of immune responses.

## 20 SUMMARY OF THE INVENTION

The present invention is based, in part, upon the discovery of a family of proteins which appear to act as a costimulator of T cell activation. In particular, the invention provides mammalian, e.g., rodent and primate,  
25 genes designated m312C2 and h312C2, respectively, which are expressed in the thymus, and are induced on T cells and spleen cells following activation. Engagement of 312C2 appears stimulate proliferation of T cell clones, antigen-specific proliferation and cytokine production by T cells,  
30 and appears to potentiate T cell expansion or apoptosis. The mouse and human embodiments are described in greater detail, but the invention encompasses related mammalian genes, proteins, antibodies, and uses thereof. Functional equivalents exhibiting significant sequence homology are  
35 available from other mammalian and non-mammalian species. Moreover, the ligand of 312C2 can function as its binding partner to stimulate other cells expressing the antigen.

The present invention provides a substantially pure or recombinant 312C2 protein or peptide fragment thereof. The protein or polypeptide is expressed, e.g., activated T cells or specifically binds to antibodies generated against SEQ ID NO: 2 or 4. Some embodiments involve a protein or peptide selected from a protein or peptide from a warm blooded animal selected from the group of birds and mammals, including a rodent or primate. The groups further consist of a protein or peptide which comprises at least one polypeptide segment of SEQ ID NO: 2 or 4; is not glycosylated; is in a buffered solulation; is attached to a solid substrate; exhibits a plurality of epitopes from SEQ ID NO: 2 or 4; is synthetically labeled; is conjugated to a chemical moiety; is a 5-fold or less substitution from a natural sequence; or is a deletion or insertion variant from a natural sequence. The protein or peptide can comprise a sequence from the extracellular or the intracellular portion of a 312C2; or be a fusion protein.

The invention also provides a recombinant nucleic acid comprising sequence at least about 70% identity over a stretch of at least about 30 nucleotides to a 312C2 nucleic acid sequence of SEQ ID NO: 1, 3 or 5, useful, e.g., as a probe or PCR primer for a related gene. Another embodiment further encodes a polypeptide sharing a plurality of specific epitopes and comprising at least about 60% identity over a stretch of at least about 20 amino acids to a 312C2 sequence of SEQ ID NO: 2 or 4.

Another embodiment is a sterile composition comprising a 312C2 protein and a pharmaceutically acceptable carrier.

Other compositions may combine said entities with an agonist or antagonist of other T cell signaling molecules, e.g., signaling entities through the T cell receptor, CD40, CD40 ligand, CTLA-8, CD28, B7, B70, BAS-1, SLAM, etc.

The invention also embraces an antibody which specifically binds a 312C2 protein or peptide, e.g., wherein the 312C2 is a mammalian protein, including a mouse; the antibody is raised against a purified 312C2

peptide sequence of SEQ ID NO: 2 or 4; the antibody is a monoclonal antibody; the antibody is detectably labeled; the antibody is attached to a solid substrate; or the antibody is in a sterile or buffered composition. The antibodies also make available a method of purifying a 312C2 protein or peptide from other materials in a mixture comprising contacting the mixture to an anti-312C2 antibody, and separating bound 312C2 from other materials.

Another aspect of the invention is an isolated or recombinant nucleic acid capable of encoding a 312C2 protein or peptide, including a nucleic acid which encodes a mature polypeptide sequence of SEQ ID NO: 2 or 4; which includes a sequence of SEQ ID NO: 1, 3 or 5; which encodes a sequence from an extracellular domain of a natural 312C2; which encodes a sequence from an intracellular domain of a natural 312C2; which is detectably labeled; which is attached to a solid substrate; or is in a sterile composition. Such nucleic acid embodiments also include an expression or replicating vector.

Also provided is a method of expressing a 312C2 peptide by expressing a nucleic acid encoding a 312C2 polypeptide. The invention also provides a cell, tissue, organ, or organism comprising a nucleic acid encoding a 312C2 peptide.

The invention also provides a kit containing a substantially pure 312C2 or fragment; an antibody or receptor which specifically binds a 312C2; or a nucleic acid, or its complement, encoding a 312C2 or peptide. This kit also provides methods for detecting in a sample the presence of a nucleic acid, protein, or antibody, comprising testing said sample with such a kit.

The invention also supplies methods of modulating the physiology of a cell comprising contacting said cell with a substantially pure 312C2 or a fragment thereof; or with an antibody or ligand which specifically binds a 312C2; or with a nucleic acid encoding a 312C2 or a peptide fragment thereof. Certain preferred embodiments include a method where the cell is a T cell and the modulating of physiology

is activation of the T cell or apoptosis of the T cell; or where the cell is in a tissue and/or in an organism.

The invention further provides a method of treating a patient having an abnormal immune response by administering  
5 an effective dose of an antibody or binding partner specific for 312C2; a 312C2 protein or polypeptide; or a nucleic acid encoding a 312C2 peptide. The abnormal immune response is characterized by a T cell immune deficiency; chronic inflammation; or tissue rejection.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

## I. Definitions

The terms "nucleic acid" "probe", or "primer" include  
5 reference to a deoxyribonucleotide, ribonucleotide, or  
mixed polymer in either single- or double-stranded form,  
and unless otherwise limited, encompasses known analogs of  
natural polynucleotides that hybridize to nucleic acids in  
manner similar to naturally occurring polynucleotides.

10 Unless otherwise indicated, a particular nucleic acid  
sequence includes the perfect complementary sequence  
thereof. Eukaryotic nucleic acids are nucleic acids from  
eukaryotic cells, preferably cells of multicellular  
eukaryotes.

15 Unless otherwise indicated, nucleic acids are written  
left to right in 5' to 3' orientation; amino acid sequences  
are written left to right in amino to carboxy orientation,  
respectively. Numeric ranges are inclusive of the numbers  
defining the range. The terms defined below are more fully  
20 defined by reference to the Specification as a whole.

The term "recombinant" when used with reference to a  
cell, or nucleic acid, or vector, includes reference to a  
cell, or nucleic acid, or vector, that has been modified by  
the introduction of a heterologous nucleic acid or the  
25 alteration of a native nucleic acid to a form not native to  
that cell, or that the cell is derived from a cell so  
modified. Thus, for example, recombinant cells express  
genes that are not found within the native (non-  
recombinant) form of the cell or express native genes that  
30 are otherwise abnormally expressed, under expressed, or not  
expressed at all.

The term "subsequence" in the context of a referenced  
nucleic acid sequence includes reference to a contiguous  
sequence from the nucleic acid having fewer nucleotides in  
35 length than the referenced nucleic acid. In the context of  
a referenced protein, polypeptide, or peptide sequence  
(collectively, "protein"), "subsequence" refers to a

contiguous sequence from the referenced protein having fewer amino acids than the referenced protein. The terminus of such subsequences include all combinations consistent with a defined length.

5 Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

10 "Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or  
 15 where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU  
 20 all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations", which are one  
 25 species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes equivalents which encompass every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG,  
 30 which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence. Substitutions with functionally equivalent  
 35 unusual nucleotides or analogs are intended, e.g., inositol, etc.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid.

Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

See also, Creighton (1984) Proteins W.H. Freeman and Company.

By "contiguous amino acids from" in the context of a specified number of amino acid residues from a specified sequence, is meant a sequence of amino acids of the specified number from within the specified reference sequence which has the identical order of amino acids each of which is directly adjacent to the same amino acids as in the reference sequence.

The term "polypeptide" as used herein includes a significant fragment or segment, and encompasses a stretch of amino acid residues of at least about 8 amino acids, generally at least about 12 amino acids, typically at least about 16 amino acids, preferably at least about 20 amino acids, and, in particularly preferred embodiments, at least about 30 or more amino acids, e.g., 40, 50, 60, 70, 80, 100, etc. The ends may be are virtually all combinations consistent with length.

The term "plurality of non-overlapping fragments" encompasses a series of polypeptide fragments or segments. A plurality includes 2, 3, 4, 5, etc., polypeptide fragments.

5       The terms "biologically pure" or "isolated" refer to material which is substantially or essentially free from components which normally accompany or interact with it as found in its naturally occurring environment. The isolated material optionally comprises material not found with the  
10 material in its natural environment.

      The phrase "encodes a protein" in the context of nucleic acids includes those nucleic acids encoding naturally occurring proteins or derivatives of natural proteins, but which are deliberately modified or engineered  
15 to no longer hybridize to a natural gene encoding the protein of natural origin under the stated conditions.

      A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of  
20 from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-  
25 known in the art. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482; by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-445; by the search for similarity  
30 method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444; by computerized implementations of these algorithms (including, but not limited to CLUSTAL in the PC/Gene program by Intelligenetics, Mountain View, California, GAP, BESTFIT, BLAST, FASTA, and TFASTA in the  
35 Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wisconsin, USA); the CLUSTAL program is well described by Higgins and Sharp



(1988) Gene 73:237-244 and Higgins and Sharp (1989) CABIOS 5:151-153; Corpet, et al. (1988) Nucleic Acids Research 16:10881-90; Huang, et al. (1992) Computer Applications in the Biosciences 8:155-65, and Pearson, et al. (1994)

- 5 Methods in Molecular Biology 24:307-31. Alignment is also often performed by inspection and manual alignment.

The terms "identical" or "sequence identity" in the context of two nucleic acid or polypeptide sequences includes reference to the residues in the two sequences which are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g. charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., according to the algorithm of Meyers and Miller (1988) Computer Applic. Biol. Sci. 4:11-17, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California, USA).

- 35 The terms "substantial identity" or "similarity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 60% sequence identity, preferably at least 80%, more preferably at least

90%, and most preferably at least 95%, compared to a reference sequence using, e.g., the programs described above (preferably BLAST) using standard parameters. One indication that two nucleic acid sequences are

5 substantially identical is that the polypeptide which the first nucleic acid encodes is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.

Another indication that two nucleic acid sequences

10 have substantial identity is that the two molecules hybridize to each other under "moderate stringency hybridization conditions" (or "moderate conditions") or better. Exemplary "moderate stringency hybridization conditions" include a hybridization in a buffer of 40%

15 formamide, 1 M NaCl, 1% SDS at 37° C, and a wash in 1X SSC at 45° C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar or higher

20 stringency. Nucleic acids which do not hybridize to each other under moderate stringency hybridization conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created, e.g., using

25 the maximum codon degeneracy permitted by the genetic code.

The terms "substantial identity" or "similarity" in the context of a peptide indicates that a peptide comprises a sequence with at least 60% sequence identity to a reference sequence, usually at least 70%, preferably 80%,

30 more preferably 85%, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window. Preferably, optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443. An

35 indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a

peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Generally, similarity is determined using a comparison window having a length of any number from 20 contiguous positions at various positions in the respective molecules to the number of residues in the full-length core region sequence, where the comparison window is within the core sequence.

The terms "oligonucleotide" or "polynucleotide" probes include reference to both double stranded and single stranded DNA or RNA. The terms also refer to synthetically or recombinantly derived sequences essentially free of non-nucleic acid contamination.

As used herein, "contact" or "contacting" means to place in direct physical association, e.g., mixing of solutions.

"Biological sample" as used herein is a sample of biological tissue or fluid that contains, or is being tested for presence of, 312C2 protein, or another of described composition, e.g., nucleic acid or protein. Such samples include, but are not limited to, sputum, amniotic fluid, blood, blood cells, e.g., white cells, or tissue, e.g., spleen, thymus, bone marrow, or lymph node.

Biological samples may also include sections of tissues such as frozen sections taken for histological purposes. Examples of biological samples include a cell sample from nervous, muscular, glandular or epithelial tissue or from the immune system (e.g., T cells). A biological sample is typically obtained from a eukaryotic organism, preferably a multicellular eukaryotes such as insect, protozoa, birds, fish, reptiles, and preferably a mammal such as rat, mice, cow, dog, guinea pig, pig, goat, or rabbit, and most preferably a primate such as macaques, chimpanzees, or humans.

An "expression vector" is a nucleic acid construct, typically generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit

transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed, and a promoter.

5       The phrase "functional effects" in the context of assays for testing compounds affecting the 312C2 includes the determination of any parameter that is indirectly or directly under the influence of the 312C2. It includes changes such as increases or decreases of transcription or  
10       second messenger or lymphokine release.

By "selectively hybridizing" or "selective hybridization" or "selectively hybridizes" is meant hybridization, under stringent hybridization conditions, of a nucleic acid sequence to a specified nucleic acid target  
15       sequence to a detectably greater degree than its hybridization to non-target nucleic acid sequences and/or to the substantial exclusion of non-target nucleic acids. Selectively hybridizing sequences typically have at least 80% sequence identity, usually 90% sequence identity,  
20       preferably 95% identity, more preferably 98% identity, and most preferably 100% sequence identity (i.e., complementary) with each other over lengths which typically start from about 10 nucleotides, e.g., 13, 17, 20, 23, 26, 29, 32, etc. "Percentage of sequence identity" is  
25       determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions  
30       or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched  
35       positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

The terms "stringent conditions" or "stringent hybridization conditions" refer to conditions under which a probe will hybridize to its target sequence, to a detectably greater degree than other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5° C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30% formamide, 1 M NaCl, 1% SDS at 37° C, and a wash in 2X SSC at 50° C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37° C, and a wash in 0.1X SSC at 60° C.

"Stringent hybridization conditions" or "stringent conditions" in the context of nucleic acid hybridization assay formats are sequence dependent, and are different under different environmental parameters. An extensive guide to the hybridization of nucleic acids is found e.g., in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York. Stringent conditions are sequence-dependent and

will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures.

By "hybridization complex" is meant a duplex nucleic acid sequence formed by selective hybridization of two single-stranded nucleic acid sequences with each other.

By "host cell" is meant a cell which is manipulated to contain and, in certain instances, express a molecule, usually a nucleic acid. Host cells may be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells.

The term "antibody" also includes antigen binding forms of antibodies (e.g., Fab, F(ab)<sub>2</sub>). The term "antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind and recognize an analyte (antigen). Antibodies exist, e.g., as intact immunoglobulins or as a number of well characterized fragments e.g., produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab')<sub>2</sub>, a dimer of Fab which itself is a light chain joined to V<sub>H</sub>-C<sub>H</sub>1 by a disulfide bond. The F(ab')<sub>2</sub> may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab')<sub>2</sub> dimer into an Fab' monomer. The Fab' monomer is essentially an Fab with part of the hinge region, see, e.g., Paul (ed.) (1993) Fundamental Immunology, 3rd ed., Raven Press, N.Y. While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, is often functionally equivalent to antibody fragments such as single chain Fv, chimeric antibodies (i.e., comprising constant and variable regions from different species), humanized antibodies (i.e., comprising a complementarity determining region (CDR) from a non-human

source) and heteroconjugate antibodies (e.g., bispecific antibodies).

By "immunologically reactive conditions" is meant conditions which allow an antibody, generated to a particular epitope, to bind to that epitope to a detectably greater degree than the antibody binds to substantially all other epitopes. Immunologically reactive conditions are dependent upon the format of the antibody binding reaction and typically are those utilized in immunoassay protocols. See Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions.

By "antibody reactive to a protein" is meant the protein is "specifically immunoreactive with an antibody."

The phrase "specifically immunoreactive with an antibody", or "specifically binds to an antibody" when referring to a protein or peptide, refers to a binding reaction between an antibody and a protein having an epitope recognized by the antigen binding site of the antibody. This binding reaction is determinative of the presence of a protein having the recognized epitope amongst the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a protein having the recognized epitope and bind, if at all, to a detectably lesser degree to other proteins lacking the epitope which are present in the sample.

Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies raised to the 312C2 of SEQ ID NO: 2 or 4 can be selected from to obtain antibodies specifically immunoreactive with that particular protein and not with other proteins. The proteins used as immunogens can be in native conformation or denatured, e.g., so as to provide a linear epitope. Preferably, antibody preparations which specifically recognize multiple epitopes will be used.

A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

By "antigen" is meant a substance to which an antibody can be generated and/or to which the antibody is specifically immunoreactive with. An antibody immunologically reactive with a particular antigen can be generated in vivo or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. See, e.g., Huse et al. (1989) Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-546; and Vaughan et al. (1996) Nature Biotechnology, 14:309-314.

By "transfected" is meant the introduction of a nucleic acid into a eukaryotic cell where the nucleic acid may be incorporated into the genome of the cell (i.e., chromosome, plasmid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA). The transfection can be in vivo or ex vivo. "Ex vivo" means outside the body of the organism from which a cell or cells is obtained or from which a cell line is isolated. Ex vivo transfection is preferably followed by re-infusion of the cells back into the organism. In contrast, by "in vivo" is meant within the body of the organism from which the cell was obtained or from which a cell line is isolated.

The term "binding composition" refers to molecules that bind with specificity to 312C2, e.g., in a cell adhesion pairing type fashion, or an antibody-antigen interaction. It also includes compounds, e.g., proteins, which specifically associate with 312C2, including in a natural physiologically relevant protein-protein



interaction, either covalent or non-covalent. The molecule may be a polymer, or chemical reagent. A functional analog may be an antigen with structural modifications, or it may be a molecule which has a molecular shape which interacts with the appropriate binding determinants. The compounds may serve as agonists or antagonists of the binding interaction, see, e.g., Goodman, et al. (eds.) (1990) Goodman & Gilman's: The Pharmacological Bases of Therapeutics (8th ed.), Pergamon Press.

Substantially pure typically means that the protein is free from other contaminating proteins, nucleic acids, or other biologicals with which it is associated in the original source organism. Purity may be assayed by standard methods, typically by weight, and will ordinarily be at least about 40% pure, generally at least about 50% pure, often at least about 60% pure, typically at least about 80% pure, preferably at least about 90% pure, and in most preferred embodiments, at least about 95% pure. Carriers or excipients will often be added, or aqueous buffers or organic solvents used in certain situations.

## II. General

The present invention provides amino acid sequences and DNA sequences encoding various mammalian proteins which are antigens found in the early stages of T cell activation, e.g., which can activate a T cell. Among these proteins are antigens which modulate, e.g., induce or prevent proliferation or differentiation of T cells, among other physiological effects. The full length antigens, and fragments, or antagonists will be useful in physiological modulation of cells expressing the antigen. The proteins will also be useful as antigens, e.g., immunogens, for raising antibodies to various epitopes on the protein, both linear and conformational epitopes. The molecule may be useful in defining or isolating functional T cell or NK cell subsets.

A cDNA encoding mouse 312C2 was isolated from an activated pro T-cell cDNA library, see Kelner, et al. (1994) Science 266:13995-1399. The mouse 312C2 cDNA contains a stretch of about 1073 bp in length and contained one large open reading frame encoding a type I transmembrane protein. Structural features include an N-terminal leader sequence of about 19 amino acids, an extracellular region of about 153 amino acids, a hydrophobic presumptive membrane spanning portion of about 25 amino acids, and a presumptive cytoplasmic domain of about 50 amino acids. See SEQ ID NO: 2. A human cDNA was isolated using the mouse clone to probe a human anergic T cell library designated HY06. See SEQ ID NO: 3 and 4. A transmembrane region may begin at about amino acid 155 and end at about amino acid 185 based on hydrophobicity analysis. The rodent and primate sequences can be aligned.

312C2 exhibits structural motifs characteristic of a member of the TNF receptor family, with numerous cysteine repeats. Compare, e.g., with the CD40, OX40, TNF receptor, NGF receptor, and FASL receptor. The intracellular portion 312C2 does not contain a death domain as described, e.g., in Pan, et al. (1997) Science 277:815-818; and Sheridan, et al. (1997) Science 277:818-821. Lack of the death domain motif may indicate that 312C2 is likely to work in the control of proliferation rather than apoptosis.

As used herein, the term "mouse 312C2" shall encompass, when used in a protein context, a protein having amino acid sequence shown in SEQ ID NO: 2, or a significant fragment of such a protein, or another highly homologous protein derived from mouse. The term "human 312C2" shall encompass, when used in a protein context, a protein having amino acid sequence shown in SEQ ID NO: 4, or a significant fragment of such a protein, or another highly homologous protein derived from human.

The natural antigens are capable of mediating various biochemical responses which lead to biological or physiological responses in target cells. The embodiments

characterized herein are from mouse and human, but other species and tissue specific variants exist. Additional sequences for proteins in other mammalian species, e.g., primates and rodents, should also be available. See below.

- 5 The descriptions below are directed, for exemplary purposes, to a mouse or human 312C2, but are likewise applicable to related embodiments from other species.

### III. Purified 312C2

- 10 The mouse 312C2 nucleic acid sequence is shown in SEQ ID NO: 1, and the amino acid sequence is shown in SEQ ID NO: 2, the human 312C2 nucleic acid sequence is shown in SEQ ID NO: 3, and the corresponding amino acid sequence is shown in SEQ ID NO: 4. A reverse translation of the human  
15 312C2 sequence is shown in SEQ ID NO: 5. These amino acid sequences, provided amino to carboxy, are important in providing sequence information about the antigen allowing for distinguishing the protein from other proteins and exemplifying numerous variants. Moreover, the peptide  
20 sequences allow preparation of peptides to generate antibodies to recognize such segments, and nucleotide sequences allow preparation of oligonucleotide probes, both of which are strategies for detection or isolation, e.g., cloning, of genes encoding such sequences.

- 25 The mouse 312C2 nucleotide and predicted amino-acid sequence, particularly the predicted leader sequence runs from about Met1 through Gly19, though natural boundaries may be different, also depending upon cell type. A polyadenylation signal occurs at nucleotide position 1010.  
30 The poly A tail begins at position 1034. See SEQ ID NO: 1 and 2. The transmembrane domain is predicted to encompass amino acids beginning at about 154 through about 179.

- In human the putative leader sequence runs from about Met1 through about Leu18. The transmembrane domain is  
35 predicted to begin at out amino acid 153 through about 182. Again the natural boundaries may vary.

Antibodies to these proteins typically bind to a 312C2 with high affinity, e.g., at least about 100 nM, usually better than about 30 nM, preferably better than about 10 nM, and more preferably at better than about 3 nM.

- 5 Homologous proteins would be found in mammalian species other than mouse, e.g., primates or rodents. Non-mammalian species should also possess structurally or functionally related genes and proteins, e.g., birds or amphibians.

- 10 Solubility of a polypeptide or fragment depends upon the environment and the polypeptide. Many parameters affect polypeptide solubility, including temperature, electrolyte environment, size and molecular characteristics of the polypeptide, and nature of the solvent. Typically, the temperature at which the polypeptide is used ranges  
15 from about 4° C to about 65° C. Usually the temperature at use is greater than about 18° C. For diagnostic purposes, the temperature will usually be about room temperature or warmer, but less than the denaturation temperature of components in the assay. For therapeutic purposes, the  
20 temperature will usually be body temperature, typically about 37° C for humans and mice, though under certain situations the temperature may be raised or lowered in situ or in vitro.

- The size and structure of the polypeptide should  
25 generally be in a substantially stable state, and usually not in a denatured state. The polypeptide may be associated with other polypeptides in a quaternary structure, e.g., to confer solubility, or associated with lipids or detergents in a manner which approximates natural  
30 lipid bilayer interactions. In certain contexts, e.g., Western blots, the protein will be denatured, and/or attached to a solid substrate, e.g., in an affinity column.

- The solvent and electrolytes will usually be a biologically compatible buffer, of a type used for  
35 preservation of biological activities, and will usually approximate a physiological aqueous solvent. Usually the solvent will have a neutral pH, typically between about 5

and 10, and preferably about 7.5. On some occasions, one or more detergents will be added, typically a mild non-denaturing one, e.g., CHS (cholesteryl hemisuccinate) or CHAPS (3-[3-cholamidopropyl]dimethylammonio]-1-propane sulfonate), or a low enough concentration as to avoid significant disruption of structural or physiological properties of the protein.

#### A. Physical Variants

10 This invention also encompasses proteins or peptides having substantial amino acid sequence identity with the amino acid sequence of the 312C2. The variants include species, polymorphic, or allelic variants.

Amino acid sequence homology, or sequence identity, is  
15 determined by optimizing residue matches, if necessary, by introducing gaps as required. See also Needleham, et al. (1970) J. Mol. Biol. 48:443-453; Sankoff, et al. (1983) Chapter One in Time Warps, String Edits, and Macromolecules: The Theory and Practice of Sequence  
20 Comparison, Addison-Wesley, Reading, MA; and software packages from IntelliGenetics, Mountain View, CA; and the University of Wisconsin Genetics Computer Group, Madison, WI. Sequence identity changes when considering conservative substitutions as matches. Conservative  
25 substitutions typically include substitutions within the following groups: glycine, alanine, valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Homologous amino acid sequences  
30 are typically intended to include natural polymorphic or allelic and interspecies variations in each respective protein sequence. Typical homologous proteins or peptides will have from 25-100% identity (if gaps can be introduced), to 50-100% identity (if conservative  
35 substitutions are included) with the amino acid sequence of the 312C2. Identity measures will be at least about 35%, generally at least about 40%, often at least about 50%,

typically at least about 60%, usually at least about 70%, preferably at least about 80%, and more preferably at least about 90%.

The isolated 312C2 DNA can be readily modified by nucleotide substitutions, nucleotide deletions, nucleotide insertions, and inversions of nucleotide stretches. These modifications result in novel DNA sequences which encode these antigens, their derivatives, or proteins having similar physiological, immunogenic, antigenic, or other functional activity. These modified sequences can be used to produce mutant antigens or to enhance expression. Enhanced expression may involve gene amplification, increased transcription, increased translation, and other mechanisms. "Mutant 312C2" encompasses a polypeptide otherwise falling within the sequence identity definition of the 312C2 as set forth above, but having an amino acid sequence which differs from that of 312C2 as normally found in nature, whether by way of deletion, substitution, or insertion. This generally includes proteins having significant identity with a protein having sequence of SEQ ID NO: 2, and as sharing various biological activities, e.g., antigenic or immunogenic, with those sequences, and in preferred embodiments contain most of the full length disclosed sequences. Preferred variants will share a plurality of immune epitopes with the recited sequences, or equivalent proteins. Full length sequences will typically be preferred, though truncated versions will also be useful, likewise, genes or proteins found from natural sources are typically most desired. Similar concepts apply to different 312C2 proteins, particularly those found in various warm blooded animals, e.g., mammals and birds. These descriptions are generally meant to encompass all 312C2 proteins, not limited to the particular mouse or human embodiments specifically discussed.

312C2 mutagenesis can also be conducted by making amino acid insertions or deletions. Substitutions, deletions, insertions, or any combinations may be generated

to arrive at a final construct. Insertions include amino-  
or carboxy- terminal fusions. Random mutagenesis can be  
conducted at a target codon and the expressed mutants can  
then be screened for the desired activity. Methods for  
5 making substitution mutations at predetermined sites in DNA  
having a known sequence are well known in the art, e.g., by  
M13 primer mutagenesis or polymerase chain reaction (PCR)  
techniques. See, e.g., Sambrook, et al. (1989); Ausubel,  
et al. (1987 and Supplements); and Kunkel, et al. (1987)  
10 Methods in Enzymol. 154:367-382.

The present invention also provides recombinant  
proteins, e.g., heterologous fusion proteins using segments  
from these proteins. A heterologous fusion protein is a  
fusion of proteins or segments which are naturally not  
15 normally fused in the same manner. A similar concept  
applies to heterologous nucleic acid sequences.

In addition, new constructs may be made from combining  
similar functional domains from other proteins. For  
example, target-binding or other segments may be "swapped"  
20 between different new fusion polypeptides or fragments.  
See, e.g., Cunningham, et al. (1989) Science 243:1330-1336;  
and O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992.

The phosphoramidite method described by Beaucage and  
Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce  
25 suitable synthetic DNA fragments. A double stranded  
fragment will often be obtained either by synthesizing the  
complementary strand and annealing the strand together  
under appropriate conditions or by adding the complementary  
strand using DNA polymerase with an appropriate primer  
30 sequence, e.g., PCR techniques.

#### B. Functional Variants

The blocking of physiological response to 312C2s may  
result from the inhibition of binding of the antigen to its  
35 binding partner, e.g., another of itself, likely through  
competitive inhibition. Thus, in vitro assays of the  
present invention will often use isolated protein,

membranes from cells expressing a membrane associated recombinant 312C2, soluble fragments comprising antigen binding segments of these proteins, or fragments attached to solid phase substrates. These assays will also allow  
5 for the diagnostic determination of the effects of either binding segment mutations and modifications, or antigen mutations and modifications, e.g., 312C2 analogs. Structure-activity analysis will be performed with mutational variants.

10 This invention also contemplates the use of competitive drug screening assays, e.g., where neutralizing antibodies to antigen or binding fragments compete with a test compound for binding to the protein, e.g., of natural protein sequence.

15 "Derivatives" of 312C2 antigens include amino acid sequence mutants from naturally occurring forms, glycosylation variants, and covalent or aggregate conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities  
20 to groups which are found in 312C2 amino acid side chains or at the N- or C- termini, e.g., by standard means. See, e.g., Lundblad and Noyes (1988) Chemical Reagents for Protein Modification, vols. 1-2, CRC Press, Inc., Boca Raton, FL; Hugli (ed.) (1989) Techniques in Protein  
25 Chemistry, Academic Press, San Diego, CA; and Wong (1991) Chemistry of Protein Conjugation and Cross Linking, CRC Press, Boca Raton, FL.

In particular, glycosylation alterations are included, e.g., made by modifying the glycosylation patterns of a  
30 polypeptide during its synthesis and processing, or in further processing steps. See, e.g., Elbein (1987) Ann. Rev. Biochem. 56:497-534. Also embraced are versions of the peptides with the same primary amino acid sequence which have other minor modifications, including  
35 phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.



Fusion polypeptides between 312C2s and other homologous or heterologous proteins are also provided. Many cytokine receptors or other surface proteins are multimeric, e.g., homodimeric entities, and a repeat  
5 construct may have various advantages, including lessened susceptibility to proteolytic cleavage. Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with a segment or domain of a protein, e.g., a receptor-binding segment, so that the presence or location of the  
10 fused ligand may be easily determined. See, e.g., Dull, et al., U.S. Patent No. 4,859,609. Other gene fusion partners include bacterial  $\beta$ -galactosidase, trpE, Protein A,  $\beta$ -lactamase, alpha amylase, alcohol dehydrogenase, yeast alpha mating factor, and detection or purification tags  
15 such as a FLAG sequence or His6 sequence. See, e.g., Godowski, et al. (1988) Science 241:812-816.

Fusion peptides will typically be made by either recombinant nucleic acid methods or by synthetic polypeptide methods. Techniques for nucleic acid  
20 manipulation and expression are described generally, e.g., in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), vols. 1-3, Cold Spring Harbor Laboratory; and Ausubel, et al. (eds.) (1993) Current Protocols in Molecular Biology, Greene and Wiley, NY. Techniques for  
25 synthesis of polypeptides are described, e.g., in Merrifield (1963) J. Amer. Chem. Soc. 85:2149-2156; Merrifield (1986) Science 232:341-347; Atherton, et al. (1989) Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford; and Grant (1992) Synthetic Peptides: A  
30 User's Guide, W.H. Freeman, NY.

This invention also contemplates the use of derivatives of 312C2s other than variations in amino acid sequence or glycosylation. Such derivatives may involve covalent or aggregative association with chemical moieties.  
35 Covalent or aggregative derivatives will be useful as immunogens, as reagents in immunoassays, or in purification methods such as for affinity purification of binding

partners, e.g., other antigens. A 312C2 can be immobilized by covalent bonding to a solid support such as cyanogen bromide-activated SEPHAROSE, by methods which are well known in the art, or adsorbed onto polyolefin surfaces, with or without glutaraldehyde cross-linking, for use in the assay or purification of anti-312C2 antibodies or an alternative binding composition. Western blot techniques are also common. The 312C2s can also be labeled with a detectable group, e.g., for use in diagnostic assays. Purification of 312C2 may be effected by an immobilized antibody or complementary binding partner.

A solubilized 312C2 or fragment of this invention can be used as an immunogen for the production of antisera or antibodies specific for binding to the antigen or fragments thereof. Purified antigen can be used to screen or purify monoclonal antibodies or antigen-binding fragments, encompassing antigen binding fragments of natural antibodies, e.g., Fab, Fab', F(ab)<sub>2</sub>, etc. Purified 312C2s can also be used as a reagent to detect antibodies generated in response to the presence of elevated levels of the antigen or cell fragments containing the antigen, both of which may be diagnostic of an abnormal or specific physiological or disease condition. This invention contemplates antibodies raised against amino acid sequences encoded by nucleotide sequence shown in SEQ ID NO: 1, or fragments of proteins containing it. In particular, this invention contemplates antibodies having binding affinity to or being raised against specific fragments which are predicted to lie outside of the lipid bilayer, both extracellular or intracellular.

The present invention contemplates the isolation of additional closely related species variants. Southern and Northern blot analysis should establish that similar genetic entities exist in other mammals. It is likely that 312C2s are widespread in species variants, e.g., rodents, lagomorphs, carnivores, artiodactyla, perissodactyla, and primates.

The invention also provides means to isolate a group of related antigens displaying both distinctness and similarities in structure, expression, and function. Elucidation of many of the physiological effects of the molecules will be greatly accelerated by the isolation and characterization of additional distinct species variants of them. In particular, the present invention provides useful probes for identifying additional homologous genetic entities in different species.

The isolated genes will allow transformation of cells lacking expression of a corresponding 312C2, e.g., either species types or cells which lack corresponding antigens and exhibit negative background activity. This should allow analysis of the function of 312C2 in comparison to untransformed control cells.

Dissection of critical structural elements which effect the various activation or differentiation functions mediated through these antigens is possible using standard techniques of modern molecular biology, particularly in comparing members of the related class. See, e.g., the homolog-scanning mutagenesis technique described in Cunningham, et al. (1989) Science 243:1339-1336; and approaches used in O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992; and Lechleiter, et al. (1990) EMBO J. 9:4381-4390. Structure activity relationship can be analyzed using variants.

Intracellular functions would probably involve segments of the antigen which are normally accessible to the cytosol. However, protein internalization may occur under certain circumstances, and interaction between intracellular components and "extracellular" segments may occur. The specific segments of interaction of 312C2 with other intracellular components may be identified by mutagenesis or direct biochemical means, e.g., cross-linking or affinity methods. Structural analysis by crystallographic or other physical methods will also be applicable. Further investigation of the mechanism of

signal transduction will include study of associated components which may be isolatable by affinity methods or by genetic means, e.g., complementation analysis of mutants.

5 Further study of the expression and control of 312C2 will be pursued. The controlling elements associated with the antigens should exhibit differential physiological, developmental, tissue specific, or other expression patterns. Upstream or downstream genetic regions, e.g.,  
10 control elements, are of interest. In particular, physiological or developmental variants, e.g., multiple alternatively processed forms of the mouse antigen have been found. See, e.g., SEQ ID NO: 1. Thus, differential splicing of message may lead to an assortment of membrane  
15 bound forms, soluble forms, and modified versions of antigen.

With human 312C2, 6 alternatively processed forms have been isolated. Clone A8, a truncated form of 312C2, is missing 7 amino acids immediately after the transmembrane  
20 domain. See SEQ ID NO: 6. Clone A5 is identical to 312C2 for the first 105 amino acids. It is believed that the divergence may be due to an unspliced intron. See SEQ ID NO: 7. Clone G10 is identical to 312C2 for the first 202 amino acids, but then varies in the 11 amino acids after  
25 the transmembrane domain and is 76 amino acids longer in the intracellular domain. The intracellular domain of G10, like that of 312C2, does not contain a death domain. See SEQ ID NO: 8.

Structural studies of the antigens will lead to design  
30 of new antigens, particularly analogs exhibiting agonist or antagonist properties on the molecule. This can be combined with previously described screening methods to isolate antigens exhibiting desired spectra of activities.

#### 35 IV. Antibodies

Antibodies can be raised to various 312C2s, including species, polymorphic, or allelic variants, and fragments

thereof, both in their naturally occurring forms and in their recombinant forms. Additionally, antibodies can be raised to 312C2s in either their active forms or in their inactive forms, including native or denatured versions.

5 Anti-idiotypic antibodies are also contemplated.

Antibodies, including binding fragments and single chain versions, against predetermined fragments of the antigens can be raised by immunization of animals with conjugates of the fragments with immunogenic proteins.

10 Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective 312C2s, or screened for agonistic or antagonistic activity, e.g., mediated through the antigen or its binding partner. Antibodies may be  
15 agonistic or antagonistic, e.g., by sterically blocking ligand binding. These monoclonal antibodies will usually bind with at least a  $K_D$  of about 1 mM, more usually at least about 300  $\mu$ M, typically at least about 100  $\mu$ M, more typically at least about 30  $\mu$ M, preferably at least about  
20 10  $\mu$ M, and more preferably at least about 3  $\mu$ M or better.

The antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they can be screened for ability to bind to the antigens without inhibiting binding by a partner. As  
25 neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying 312C2 protein or its binding partners. See, e.g., Chan (ed.) (1987) Immunology: A Practical Guide, Academic Press, Orlando, FL; Price and Newman (eds.) (1991)  
30 Principles and Practice of Immunoassay, Stockton Press, N.Y.; and Ngo (ed.) (1988) Nonisotopic Immunoassay, Plenum Press, N.Y. Cross absorptions or other tests will identify antibodies which exhibit various spectra of specificities, e.g., unique or shared species specificities.

35 Further, the antibodies, including antigen binding fragments, of this invention can be potent antagonists that bind to the antigen and inhibit functional binding or

inhibit the ability of a binding partner to elicit a biological response. They also can be useful as non-neutralizing antibodies and can be coupled to toxins or radionuclides so that when the antibody binds to antigen, a cell expressing it, e.g., on its surface, is killed. Further, these antibodies can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.

Antigen fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined polypeptides to be used as immunogens. An antigen and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology, Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962) Specificity of Serological Reactions, Dover Publications, New York; Williams, et al. (1967) Methods in Immunology and Immunochemistry, vol. 1, Academic Press, New York; and Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press, NY, for descriptions of methods of preparing polyclonal antisera.

In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al. (eds.) Basic and Clinical Immunology (4th ed.), Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.), Academic Press, New York; and particularly in Kohler and Milstein (1975) in Nature 256:495-497, which discusses one method of generating monoclonal antibodies.

Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors. See, Huse, et al. (1989) "Generation of a Large

Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-546. The polypeptides and antibodies of the present invention may be used with or without  
5 modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide  
10 variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels  
15 include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567; Moore, et al., U.S. Patent No. 4,642,334; and Queen, et al. (1989) Proc. Nat'l Acad. Sci.  
20 USA 86:10029-10033.

The antibodies of this invention can also be used for affinity chromatography in isolating the protein. Columns can be prepared where the antibodies are linked to a solid support. See, e.g., Wilchek et al. (1984) Meth. Enzymol.  
25 104:3-55.

Antibodies raised against each 312C2 will also be useful to raise anti-idiotypic antibodies. These will be useful in detecting or diagnosing various immunological conditions related to expression of the respective  
30 antigens.

#### V. Nucleic Acids

The described peptide sequences and the related reagents are useful in detecting, isolating, or identifying  
35 a DNA clone encoding 312C2, e.g., from a natural source. Typically, it will be useful in isolating a gene from mammal, and similar procedures will be applied to isolate

genes from other species, e.g., warm blooded animals, such as birds and mammals. Cross hybridization will allow isolation of 312C2 from other species. A number of different approaches should be available to successfully isolate a suitable nucleic acid clone.

The purified protein or defined peptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein can be presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual, Cold Spring Harbor Press. Alternatively, the 312C2 can be used as a specific binding reagent, and advantage can be taken of its specificity of binding, much like an antibody would be used.

For example, the specific binding composition could be used for screening of an expression library made from a cell line which expresses a 312C2. The screening can be standard staining of surface expressed antigen, or by panning. Screening of intracellular expression can also be performed by various staining or immunofluorescence procedures. The binding compositions could be used to affinity purify or sort out cells expressing the protein.

The peptide segments can also be used to predict appropriate oligonucleotides to screen a library. The genetic code can be used to select appropriate oligonucleotides useful as probes for screening. See, e.g., SEQ ID NO: 1 or 3. In combination with polymerase chain reaction (PCR) techniques, synthetic oligonucleotides will be useful in selecting correct clones from a library. Complementary sequences will also be used as probes, primers, or antisense strands. Based upon identification of the likely extracellular domain, various fragments should be particularly useful, e.g., coupled with anchored vector or poly-A complementary PCR techniques or with complementary DNA of other peptides.



This invention contemplates use of isolated DNA or fragments to encode a biologically active corresponding 312C2 polypeptides. See SEQ ID NO: 5. In addition, this invention covers isolated or recombinant DNA which encodes  
5 a biologically active, e.g., antigenic, protein or polypeptide which is capable of hybridizing under appropriate conditions with the DNA sequences described herein. Said biologically active protein or polypeptide can be an intact antigen, or fragment, and have an amino  
10 acid sequence disclosed in, e.g., SEQ ID NO: 2 or 4. Further, this invention covers the use of isolated or recombinant DNA, or fragments thereof, which encode proteins which are homologous to a 312C2 or which was isolated using cDNA encoding a 312C2 as a probe. The  
15 isolated DNA can have the respective regulatory sequences in the 5' and 3' flanks, e.g., promoters, enhancers, poly-A addition signals, and others.

An "isolated" nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a mixed polymer, which is substantially  
20 separated from other components which naturally accompany a native sequence, e.g., ribosomes, polymerases, and/or flanking genomic sequences from the originating species. The term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and  
25 includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems. A substantially pure molecule includes isolated forms of the molecule. Generally, the nucleic acid will be in a vector or fragment less than  
30 about 50 kb, usually less than about 30 kb, typically less than about 10 kb, and preferably less than about 6 kb.

An isolated nucleic acid will generally be a homogeneous composition of molecules, but will, in some embodiments, contain minor heterogeneity. This  
35 heterogeneity is typically found at the polymer ends or portions not critical to a desired biological function or activity.

A "recombinant" nucleic acid is defined either by its method of production or its structure. In reference to its method of production, e.g., a product made by a process, the process is use of recombinant nucleic acid techniques, e.g., involving human intervention in the nucleotide sequence, typically selection or production.

Alternatively, it can be a nucleic acid made by generating a sequence comprising fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude products of nature, e.g., naturally occurring mutants.

Thus, e.g., products made by transforming cells with any unnaturally occurring vector is encompassed, as are nucleic acids comprising sequence derived using any synthetic oligonucleotide process. Such is often done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site.

Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly available natural forms. Restriction enzyme recognition sites are often the target of such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design. A similar concept is intended for a recombinant, e.g., fusion, polypeptide. Specifically included are synthetic nucleic acids which, by genetic code redundancy, encode polypeptides similar to fragments of these antigens, and fusions of sequences from various different species variants. Alternatively, a heterologous promoter may be inserted upstream from a natural gene.

A significant "fragment" in a nucleic acid context is a contiguous segment of at least about 17 nucleotides, generally at least about 22 nucleotides, ordinarily at least about 29 nucleotides, more often at least about 35

nucleotides, typically at least about 41 nucleotides, usually at least about 47 nucleotides, preferably at least about 55 nucleotides, and in particularly preferred embodiments will be at least about 60 or more nucleotides.

5 A DNA which codes for a 312C2 protein will be particularly useful to identify genes, mRNA, and cDNA species which code for related or homologous proteins, as well as DNAs which code for homologs proteins from different species. There are likely homologues in other  
10 species, including primates, rodents, and birds. Various 312C2 proteins should be homologous and are encompassed herein. However, even proteins that have a more distant evolutionary relationship to the antigen can readily be isolated under appropriate conditions using these sequences  
15 if they are sufficiently homologous. Primate 312C2 proteins are of particular interest.

Recombinant clones derived from the genomic sequences, e.g., containing introns, will be useful for transgenic studies, including, e.g., transgenic cells and organisms,  
20 and for gene therapy. See, e.g., Goodnow (1992) "Transgenic Animals" in Roitt (ed.) Encyclopedia of Immunology, Academic Press, San Diego, pp. 1502-1504; Travis (1992) Science 256:1392-1394; Kuhn, et al. (1991) Science 254:707-710; Capecchi (1989) Science 244:1288;  
25 Robertson (1987)(ed.) Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, IRL Press, Oxford; and Rosenberg (1992) J. Clinical Oncology 10:180-199.

Substantial homology in the nucleic acid sequence comparison context means either that the segments, or their  
30 complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about 50% of the nucleotides, generally at least about 58%, ordinarily at least about 65%, often at least about 71%, typically at least about  
35 77%, usually at least about 85%, preferably at least about 95 to 98% or more, and in particular embodiments, as high as about 99% or more of the nucleotides. Alternatively,

substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand, or its complement, typically using a sequence of 312C2, e.g., in SEQ ID NO: 1 or 3. Typically, selective hybridization will occur when there is at least about 55% homology over a stretch of at least about 30 nucleotides, preferably at least about 75% over a stretch of about 25 nucleotides, and most preferably at least about 90% over about 20 nucleotides. See, Kanehisa (1984) Nuc. Acids Res. 12:203-213. The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will be over a stretch of at least about 17 nucleotides, usually at least about 28 nucleotides, typically at least about 40 nucleotides, and preferably at least about 75 to 100 or more nucleotides.

Stringent conditions, in referring to homology in the hybridization context, will be stringent combined conditions of salt, temperature, organic solvents, and other parameters, typically those controlled in hybridization reactions. Stringent temperature conditions will usually include temperatures in excess of about 30° C, usually in excess of about 37° C, typically in excess of about 55° C, preferably in excess of about 70° C.

Stringent salt conditions will ordinarily be less than about 1000 mM, usually less than about 400 mM, typically less than about 250 mM, preferably less than about 150 mM. However, the combination of parameters is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson (1968) J. Mol. Biol. 31:349-370.

312C2 from other mammalian species can be cloned and isolated by cross-species hybridization of closely related species. Homology may be relatively low between distantly related species, and thus hybridization of relatively closely related species is advisable. Alternatively, preparation of an antibody preparation which exhibits less species specificity may be useful in expression cloning approaches.

## VI. Making 312C2; Mimetics

DNA which encodes the 312C2 or fragments thereof can be obtained by chemical synthesis, screening cDNA

- 5 libraries, or screening genomic libraries prepared from a wide variety of cell lines or tissue samples. See, e.g., Okayama and Berg (1982) Mol. Cell. Biol. 2:161-170; Gubler and Hoffman (1983) Gene 25:263-269; and Glover (ed.) (1984) DNA Cloning: A Practical Approach, IRL Press, Oxford.
- 10 Alternatively, the sequences provided herein provide useful PCR primers or allow synthetic or other preparation of suitable genes encoding a 312C2; including, naturally occurring embodiments.

- 15 This DNA can be expressed in a wide variety of host cells for the synthesis of a full-length 312C2 or fragments which can in turn, e.g., be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified molecules; and for structure/function studies.

- 20 Vectors, as used herein, comprise plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles which enable the integration of DNA fragments into the genome of the host. See, e.g., Pouwels, et al. (1985 and Supplements) Cloning Vectors: A Laboratory Manual, Elsevier, N.Y.; and Rodriguez, et al. (1988) (eds.) Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworth, Boston, MA.
- 25

- For purposes of this invention, DNA sequences are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a preprotein or participates in directing the polypeptide to the cell membrane or in secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to a coding sequence if it is positioned to permit
- 30
- 35

translation. Usually, operably linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression. See  
 5 e.g., Rodriguez, et al., Chapter 10, pp. 205-236; Balbas and Bolivar (1990) Methods in Enzymology 185:14-37; and Ausubel, et al. (1993) Current Protocols in Molecular Biology, Greene and Wiley, NY.

Representative examples of suitable expression  
 10 vectors include pCDNA1; pCD, see Okayama, et al. (1985) Mol. Cell Biol. 5:1136-1142; pMC1neo Poly-A, see Thomas, et al. (1987) Cell 51:503-512; and a baculovirus vector such as pAC 373 or pAC 610. See, e.g., Miller (1988) Ann. Rev. Microbiol. 42:177-199.

15 It will often be desired to express a 312C2 polypeptide in a system which provides a specific or defined glycosylation pattern. See, e.g., Luckow and Summers (1988) Bio/Technology 6:47-55; and Kaufman (1990) Meth. Enzymol. 185:487-511.

20 The 312C2, or a fragment thereof, may be engineered to be phosphatidyl inositol (PI) linked to a cell membrane, but can be removed from membranes by treatment with a phosphatidyl inositol cleaving enzyme, e.g., phosphatidyl inositol phospholipase-C. This releases the antigen in a  
 25 biologically active form, and allows purification by standard procedures of protein chemistry. See, e.g., Low (1989) Biochim. Biophys. Acta 988:427-454; Tse, et al. (1985) Science 230:1003-1008; and Brunner, et al. (1991) J. Cell Biol. 114:1275-1283.

30 Now that the 312C2 has been characterized, fragments or derivatives thereof can be prepared by conventional processes for synthesizing peptides. These include processes such as are described in Stewart and Young (1984) Solid Phase Peptide Synthesis, Pierce Chemical Co.,  
 35 Rockford, IL; Bodanszky and Bodanszky (1984) The Practice of Peptide Synthesis, Springer-Verlag, New York; Bodanszky (1984) The Principles of Peptide Synthesis, Springer-

Verlag, New York; and Villafranca (ed.) (1991) Techniques in Protein Chemistry II, Academic Press, San Diego, Ca.

#### VII. Uses

5       The present invention provides reagents which will find use in diagnostic applications as described elsewhere herein, e.g., in the general description for T cell mediated conditions, or below in the description of kits for diagnosis. The antigen is useful as a marker, e.g., to  
10 identify T or NK cell subsets, or as a positive selection marker to fractionate immune subsets.

      This invention also provides reagents with significant therapeutic value. The 312C2 (naturally occurring or recombinant), fragments thereof, and antibodies thereto,  
15 along with compounds identified as having binding affinity to 312C2, should be useful in the treatment of conditions associated with abnormal physiology or development, including abnormal proliferation, e.g., cancerous conditions, or degenerative conditions. In particular,  
20 modulation of development of lymphoid cells will be achieved by appropriate therapeutic treatment using the compositions provided herein. For example, a disease or disorder associated with abnormal expression or abnormal signaling by a 312C2 should be a likely target for an  
25 agonist or antagonist of the antigen. The antigen plays a role in regulation or development of hematopoietic cells, e.g., lymphoid cells, which affect immunological responses, e.g., autoimmune disorders.

      In particular, the antigen will likely provide a  
30 costimulatory signal to T cell activation. Thus, the 312C2 will likely mediate T cell interactions with other cell types. These interactions lead, in particular contexts, to cell proliferation, enhanced cytokine synthesis by the cells, and consequential amplification of T cell  
35 proliferation.

      Moreover, the 312C2 or antagonists could redirect T cell responses, e.g., towards a Th0/Th1 pathway, or towards

a Th2 type response. Among these agonists should be various antibodies which recognize the appropriate epitopes, e.g., which mimic binding of 312C2 to its ligand. Alternatively, antibody antagonists may bind to epitopes  
5 which sterically can block partner binding.

Conversely, antagonists of 312C2, such as the naturally occurring secreted form of 312C2 or blocking antibodies, may provide a selective and powerful way to block immune responses in abnormal situations, e.g.,  
10 autoimmune disorders, including rheumatoid arthritis, systemic lupus erythrematosis (SLE), Hashimoto's autoimmune thyroiditis, as well as acute and chronic inflammatory responses in which T cell activation, expansion, and/or immunological T cell memory play an important role. See  
15 also Samter, et al. (eds.) Immunological Diseases vols. 1 and 2, Little, Brown and Co. Suppression of T cell activation, expansion, and/or cytokine release by the naturally occurring secreted form of 312C2, which can be produced in large quantities by recombinant methods, or by  
20 blocking antibodies, should be effective in many disorders in which abnormal or undesired T cell responses are of importance, e.g., in a transplantation rejection situation.

In addition, certain combination compositions with other modulators of T cell signaling would be useful. Such  
25 other signaling molecules include TcR reagents, CD40, CD40L, CTLA-8, CD28, SLAM, FAS, and their respective antagonists.

Various abnormal conditions are known in each of the cell types shown to possess 312C2 mRNA by Northern blot  
30 analysis. See Berkow (ed.) The Merck Manual of Diagnosis and Therapy, Merck & Co., Rahway, N.J.; Thorn, et al. Harrison's Principles of Internal Medicine, McGraw-Hill, N.Y.; and Weatherall, et al. (eds.) Oxford Textbook of Medicine, Oxford University Press, Oxford. Many other  
35 medical conditions and diseases involve T cells or are T cell mediated, and many of these will be responsive to treatment by an agonist or antagonist provided herein.



See, e.g., Stites and Terr (eds; 1991) Basic and Clinical Immunology Appleton and Lange, Norwalk, Connecticut; and Samter, et al. (eds) Immunological Diseases Little, Brown and Co. These problems should be susceptible to prevention or treatment using compositions provided herein.

312C2 antibodies can be purified and then administered to a patient, veterinary or human. These reagents can be combined for therapeutic use with additional active or inert ingredients, e.g., in conventional pharmaceutically acceptable carriers or diluents, e.g., immunogenic adjuvants, along with physiologically innocuous stabilizers, excipients, buffers, or preservatives. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations. This invention also contemplates use of antibodies or binding fragments thereof, including forms which are not complement binding. Sterile compositions of nucleic acids and proteins are also contemplated.

Drug screening using 312C2 or fragments thereof can be performed to identify compounds having binding affinity to or other relevant biological effects on 312C2 functions, including isolation of associated components. Subsequent biological assays can then be utilized to determine if the compound has intrinsic stimulating activity and is therefore a blocker or antagonist in that it blocks the activity of the antigen. Likewise, a compound having intrinsic stimulating activity can activate the signal pathway and is thus an agonist in that it simulates the activity of 312C2. This invention further contemplates the therapeutic use of blocking antibodies to 312C2 as antagonists and of stimulatory antibodies, e.g., A12, as agonists. This approach should be particularly useful with other 312C2 species variants.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state

of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ

5 administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage.

Various considerations are described, e.g., in Gilman, et al. (eds.) (1990) Goodman and Gilman's: The

10 Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed.

(1990), Mack Publishing Co., Easton, Penn. Methods for administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular

15 administration, transdermal diffusion, and others.

Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey. Dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10  $\mu$ M concentrations, usually less than about 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier.

20 Slow release formulations, or a slow release apparatus will often be utilized for continuous or long term administration. See, e.g., Langer (1990) Science 249:1527-1533.

312C2, fragments thereof, and antibodies to it or its fragments, antagonists, and agonists, may be administered

30 directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration. Therapeutic formulations may be administered in many conventional dosage

35 formulations. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation. Formulations

typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, topical, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn.; Avis, et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Dekker, New York; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Dekker, New York; and Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems, Dekker, New York. The therapy of this invention may be combined with or used in association with other agents, e.g., other modulators of T cell activation, e.g., CD40, CD40 ligand, CD28, CTLA-4, B7, B70, SLAM, T cell receptor signaling entities, or their respective antagonists.

Both the naturally occurring and the recombinant form of the 312C2s of this invention are particularly useful in kits and assay methods which are capable of screening compounds for binding activity to the proteins. Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of compounds in a short period. See, e.g., Fodor, et al. (1991) Science 251:767-773, which describes means for testing of binding affinity by a plurality of defined polymers synthesized on a solid substrate. The development of suitable assays can be greatly facilitated by the

availability of large amounts of purified, soluble 312C2 as provided by this invention.

Other methods can be used to determine the critical residues in the 312C2-312C2 ligand interactions.

5 Mutational analysis can be performed, e.g., see Somoza, et al. (1993) J. Exptl. Med. 178:549-558, to determine specific residues critical in the interaction and/or signaling. Both extracellular domains, involved in the homophilic interaction, or intracellular domain, which  
10 provides interactions important in intracellular signaling.

For example, antagonists can normally be found once the antigen has been structurally defined, e.g., by tertiary structure data. Testing of potential interacting  
15 analogs is now possible upon the development of highly automated assay methods using a purified 312C2. In particular, new agonists and antagonists will be discovered by using screening techniques described herein. Of particular importance are compounds found to have a combined binding affinity for a spectrum of 312C2  
20 molecules, e.g., compounds which can serve as antagonists for species variants of 312C2.

One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant DNA molecules expressing a 312C2. Cells may be  
25 isolated which express a 312C2 in isolation from other molecules. Such cells, either in viable or fixed form, can be used for standard binding partner binding assays. See also, Parce, et al. (1989) Science 246:243-247; and Owicki, et al. (1990) Proc. Nat'l Acad. Sci. USA 87:4007-4011,  
30 which describe sensitive methods to detect cellular responses.

Another technique for drug screening involves an approach which provides high throughput screening for compounds having suitable binding affinity to a 312C2 and  
35 is described in detail in Geysen, European Patent Application 84/03564, published on September 13, 1984. First, large numbers of different small peptide test

compounds are synthesized on a solid substrate, e.g., plastic pins or some other appropriate surface, see Fodor, et al. (1991). Then all the pins are reacted with solubilized, unpurified or solubilized, purified 312C2, and washed. The next step involves detecting bound 312C2.

Rational drug design may also be based upon structural studies of the molecular shapes of the 312C2 and other effectors or analogs. Effectors may be other proteins which mediate other functions in response to binding, or other proteins which normally interact with 312C2. One means for determining which sites interact with specific other proteins is a physical structure determination, e.g., x-ray crystallography or 2 dimensional NMR techniques. These will provide guidance as to which amino acid residues form molecular contact regions. For a detailed description of protein structural determination, see, e.g., Blundell and Johnson (1976) Protein Crystallography, Academic Press, New York. Structure from related TcR family genes will also provide further insight.

20

#### VIII. Kits

This invention also contemplates use of 312C2 proteins, fragments thereof, peptides, and their fusion products in a variety of diagnostic kits and methods for detecting the presence of another 312C2 or binding partner. Typically the kit will have a compartment containing either a defined 312C2 peptide or gene segment or a reagent which recognizes one or the other, e.g., 312C2 fragments or antibodies.

A kit for determining the binding affinity of a test compound to a 312C2 would typically comprise a test compound; a labeled compound, for example a binding partner or antibody having known binding affinity for 312C2; a source of 312C2 (naturally occurring or recombinant); and a means for separating bound from free labeled compound, such as a solid phase for immobilizing the molecule. Once compounds are screened, those having suitable binding

affinity to the antigen can be evaluated in suitable biological assays, as are well known in the art, to determine whether they act as agonists or antagonists to the signaling pathway. The availability of recombinant  
5 312C2 polypeptides also provide well defined standards for calibrating such assays. Histological analysis is also possible.

A preferred kit for determining the concentration of, e.g., a 312C2 in a sample would typically comprise a  
10 labeled compound, e.g., binding partner or antibody, having known binding affinity for the antigen, a source of antigen (naturally occurring or recombinant) and a means for separating the bound from free labeled compound, e.g., a solid phase for immobilizing the 312C2. Compartments  
15 containing reagents, and instructions, will normally be provided.

Antibodies, including antigen binding fragments, specific for the 312C2 or fragments are useful in diagnostic applications to detect the presence of elevated  
20 levels of 312C2 and/or its fragments. Such diagnostic assays can employ lysates, live cells, fixed cells, immunofluorescence, cell cultures, body fluids, and further can involve the detection of antigens related to the antigen in serum, or the like. Diagnostic assays may be  
25 homogeneous (without a separation step between free reagent and antigen-binding partner complex) or heterogeneous (with a separation step). Various commercial assays exist, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), enzyme-multiplied  
30 immunoassay technique (EMIT), substrate-labeled fluorescent immunoassay (SLFIA), and the like. See, e.g., Van Vunakis, et al. (1980) Meth Enzymol. 70:1-525; Harlow and Lane (1980) Antibodies: A Laboratory Manual, CSH Press, NY; and Coligan, et al. (eds.) (1993) Current Protocols in  
35 Immunology, Greene and Wiley, NY.

Anti-idiotypic antibodies may have similar use to diagnose presence of antibodies against a 312C2, as such

may be diagnostic of various abnormal states. For example, overproduction of 312C2 may result in production of various immunological reactions which may be diagnostic of abnormal physiological states, particularly in proliferative cell  
5 conditions such as cancer or abnormal activation or differentiation.

Frequently, the reagents for diagnostic assays are supplied in kits, so as to optimize the sensitivity of the assay. For the subject invention, depending upon the  
10 nature of the assay, the protocol, and the label, either labeled or unlabeled antibody or binding partner, or labeled 312C2 is provided. This is usually in conjunction with other additives, such as buffers, stabilizers, materials necessary for signal production such as  
15 substrates for enzymes, and the like. Preferably, the kit will also contain instructions for proper use and disposal of the contents after use. Typically the kit has compartments for each useful reagent. Desirably, the reagents are provided as a dry lyophilized powder, where  
20 the reagents may be reconstituted in an aqueous medium providing appropriate concentrations of reagents for performing the assay. Kits may be for solution determination, or histology in tissue samples.

Many of the aforementioned constituents of the drug  
25 screening and the diagnostic assays may be used without modification or may be modified in a variety of ways. For example, labeling may be achieved by covalently or non-covalently joining a moiety which directly or indirectly provides a detectable signal. In any of these assays, the  
30 binding partner, test compound, 312C2, or antibodies thereto can be labeled either directly or indirectly. Possibilities for direct labeling include label groups: radiolabels such as  $^{125}\text{I}$ , enzymes (U.S. Pat. No. 3,645,090) such as peroxidase and alkaline phosphatase, and  
35 fluorescent labels (U.S. Pat. No. 3,940,475) capable of monitoring the change in fluorescence intensity, wavelength shift, or fluorescence polarization. Possibilities for

indirect labeling include biotinylation of one constituent followed by binding to avidin coupled to one of the above label groups.

There are also numerous methods of separating the  
5 bound from the free 312C2, or alternatively the bound from the free test compound. The 312C2 can be immobilized on various matrixes followed by washing. . Suitable matrixes include plastic such as an ELISA plate, filters, and beads. See, e.g., Coligan, et al. (eds.) (1993) Current Protocols  
10 in Immunology, Vol. 1, Chapter 2, Greene and Wiley, NY. Other suitable separation techniques include, without limitation, the fluorescein antibody magnetizable particle method described in Rattle, et al. (1984) Clin. Chem. 30:1457-1461, and the double antibody magnetic particle  
15 separation as described in U.S. Pat. No. 4,659,678.

Methods for linking proteins or their fragments to the various labels have been extensively reported in the literature and do not require detailed discussion here. Many of the techniques involve the use of activated  
20 carboxyl groups either through the use of carbodiimide or active esters to form peptide bonds, the formation of thioethers by reaction of a mercapto group with an activated halogen such as chloroacetyl, or an activated olefin such as maleimide, for linkage, or the like. Fusion  
25 proteins will also find use in these applications.

Another diagnostic aspect of this invention involves use of oligonucleotide or polynucleotide sequences taken from the sequence of a 312C2. These sequences can be used as probes for detecting levels of the 312C2 message in  
30 samples from patients suspected of having an abnormal condition, e.g., cancer or developmental problem. Since the antigen is a marker for activation, it may be useful to determine the numbers of activated T cells to determine, e.g., when additional suppression may be called for. The  
35 preparation of both RNA and DNA nucleotide sequences, the labeling of the sequences, and the preferred size of the sequences has received ample description and discussion in



the literature. See, e.g., Langer-Safer, et al. (1982) Proc. Nat'l. Acad. Sci. 79:4381-4385; Caskey (1987) Science 236:962-967; and Wilchek et al. (1988) Anal. Biochem. 171:1-32. Histological analysis may also be performed.

- 5       Diagnostic kits which also test for the qualitative or quantitative presence of other markers are also contemplated. Diagnosis or prognosis may depend on the combination of multiple indications used as markers. Thus, kits may test for combinations of markers. See, e.g.,
- 10       Viallet, et al. (1989) Progress in Growth Factor Res. 1:89-97. Other kits may be used to evaluate T cell subsets, e.g., analysis or isolation, using conservative or destructive means.

- 15       IX. Methods for Isolating 312C2 Specific Binding Partners
- The 312C2 protein should interact with a ligand based, e.g., upon its similarity in structure and function to other cell surface antigens exhibiting similar structure and cell type specificity of expression. Methods to
- 20       isolate a ligand are made available by the ability to make purified 312C2 for screening programs. Soluble or other constructs using the 312C2 sequences provided herein will allow for screening or isolation of 312C2 specific ligands. Many methods exist for expression cloning, panning,
- 25       affinity isolation, cross-linking, genetic selection, or other means to identify a receptor ligand.

- A variety of different assays for detecting compounds capable of binding to 312C2 are used in the present invention. For instance, the binding of a test compound to
- 30       312C2 or a peptide fragment thereof can be measured directly, in the presence or absence of 312C2 polypeptide. This latter type of assay is called a direct binding assay. In addition, compounds which inhibit the binding of 312C2 to specific, preferably monoclonal, antibodies can be
- 35       identified in competitive binding assays. Both direct binding assays and competitive binding assays can be used in a variety of different formats, similar to the formats

used in immunoassays and receptor binding assays. For a description of different formats for binding assays, including competitive binding assays and direct binding assays, see Basic and Clinical Immunology 7th Edition (D. Stites and A. Terr ed.) 1991; Enzyme Immunoassay, E.T. Maggio, ed., CRC Press, Boca Raton, Florida (1980); and "Practice and Theory of Enzyme Immunoassays," P. Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers B.V. Amsterdam (1985), each of which is incorporated herein by reference.

In competitive binding assays, for example, the sample compound can compete with a labeled analyte for specific binding sites on a binding agent bound to a solid surface. In this type of format, the labeled analyte can be labeled 312C2 and the binding agent can be an antibody bound to a solid phase. Alternatively, the labeled analyte can be labeled antibody and the binding agent can be a solid phase wild type 312C2 or a fragment thereof. The concentration of labeled analyte bound to the capture agent is inversely proportional to the ability of a test compound to compete in the binding assay. The amount of inhibition of labeled analyte by the test compound depends on the binding assay conditions and on the concentrations of binding agent, labeled analyte, and test compound that are used. Under specified assay conditions, a compound is said to be capable of inhibiting the binding of 312C2 to a specific antibody in a competitive binding assay, if the amount of binding of the labeled analyte to the binding agent is decreased by 50% or preferably 90% or more. When a direct binding assay format is used, a test compound is said to bind an 312C2 when the signal measured is twice the background level or higher.

In a competitive binding assay, the sample compound competes with labeled protein for binding to a specific binding agent. As described above, the binding agent may be bound to a solid surface to effect separation of bound labeled protein from the unbound labeled protein.

Alternately, the competitive binding assay may be conducted in liquid phase, and any of a variety of techniques known in the art may be used to separate the bound labeled protein from the unbound labeled protein. Following  
5 separation, the amount of bound labeled protein is determined. The amount of protein present in the sample is inversely proportional to the amount of labeled protein binding.

Alternatively, a homogeneous binding assay may be  
10 performed in which a separation step is not needed. In these type of binding assays, the label on the protein is altered by the binding of the protein to its specific binding agent. This alteration in the labeled protein results in a decrease or increase in the signal emitted by  
15 label, so that measurement of the label at the end of the binding assay allows for detection or quantitation of the protein.

The binding assay formats described herein employ labeled assay components. The label can be in a variety of  
20 forms. The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. A wide variety of labels may be used. The component may be labeled by any one of several methods. Traditionally, a radioactive label incorporating  
25  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$  is used. Non-radioactive labels include ligands which bind to labeled antibodies, fluorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labeled ligand. The choice of label depends on  
30 sensitivity required, ease of conjugation with the compound, stability requirements, and available instrumentation. For a review of various labeling or signal producing systems which may be used, see U.S. Patent No. 4,391,904, which is incorporated herein by reference.

35 Alternatively, an expression library can be screened for specific binding to 312C2, e.g., by cell sorting, or other screening to detect subpopulations which express such

a binding component. See, e.g., Ho, et al. (1993) Proc. Nat'l Acad. Sci. USA 90:11267-11271. Alternatively, a panning method may be used. See, e.g., Seed and Aruffo (1987) Proc. Nat'l Acad. Sci. USA 84:3365-3369. A two-  
5 hybrid selection system may also be applied making appropriate constructs with the available 312C2 sequences. See, e.g., Fields and Song (1989) Nature 340:245-246.

The broad scope of this invention is best understood  
10 with reference to the following examples, which are not intended to limit the invention to specific embodiments.

## EXAMPLES

## General Methods

- Some of the standard methods are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), vols. 1-3, CSH Press, NY; Ausubel, et al., Biology, Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology, Greene and Wiley, New York; Innis, et al. (eds.) (1990) PCR Protocols: A Guide to Methods and Applications, Academic Press, N.Y. Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification" in Methods in Enzymology vol. 182, and other volumes in this series; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond, CA. Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See, e.g., Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, N.Y.; and Crowe, et al. (1992) OIAexpress: The High Level Expression & Protein Purification System QIAGEN, Inc., Chatsworth, CA. Cell culture techniques are described in Doyle, et al. (eds.) (1994) Cell and Tissue Culture: Laboratory Procedures, John Wiley and Sons, NY.
- Standard immunological techniques are described, e.g., in Hertenzenberg, et al. (eds. 1996) Weir's Handbook of Experimental Immunology vols 1-4, Blackwell Science;

Coligan (1991) Current Protocols in Immunology Wiley/Greene, NY; and Methods in Enzymology volumes. 70, 73, 74, 84, 92, 93, 108, 116, 121, 132, 150, 162, and 163.

Assays for vascular biological activities are well known in the art. They will cover angiogenic and angiostatic activities in tumor, or other tissues, e.g., arterial smooth muscle proliferation (see, e.g., Koyoma, et al. (1996) Cell 87:1069-1078), monocyte adhesion to vascular epithelium (see McEvoy, et al. (1997) J. Exp. Med. 185:2069-2077), etc. See also Ross (1993) Nature 362:801-809; Rekhater and Gordon (1995) Am. J. Pathol. 147:668-677; Thyberg, et al. (1990) Atherosclerosis 10:966-990; and Gumbiner (1996) Cell 84:345-357.

Assays for neural cell biological activities are described, e.g., in Wouterlood (ed. 1995) Neuroscience Protocols modules 10, Elsevier; Methods in Neurosciences Academic Press; and Neuromethods Humana Press, Totowa, NJ. Methodology of developmental systems is described, e.g., in Meisami (ed.) Handbook of Human Growth and Developmental Biology CRC Press; and Chrispeels (ed.) Molecular Techniques and Approaches in Developmental Biology Interscience.

FACS analyses are described in Melamed, et al. (1990) Flow Cytometry and Sorting Wiley-Liss, Inc., New York, NY; Shapiro (1988) Practical Flow Cytometry Liss, New York, NY; and Robinson, et al. (1993) Handbook of Flow Cytometry Methods Wiley-Liss, New York, NY. Fluorescent labeling of appropriate reagents was performed by standard methods.

EXAMPLE 1: Cloning of Mouse 312C2  
Antibodies and flow-cytometric sorting

$\alpha\beta$ Tcr+CD4-CD8- (DN) thymocytes were sorted using CD4/CD8a-PE and Tcr $\alpha\beta$ -FITC mAbs (PharMingen, San Diego, CA). See Zlotnik, et al. (1992) J. Immunol. 4:1211-1215.

The sorted cells (approximately  $5 \times 10^5$ ) were stimulated on solid-phase anti-CD3 for 24 h and were then expanded and cultured in IL-2 (500 U/ml) and IL-7 (100 U/ml) for one

week (to approximately  $1 \times 10^8$  cells). Cells were either harvested after one week in culture or stimulated again for 6 h on anti-CD3 and then harvested. See Kelner, et al. (1994) Science 266:1395-1399.

5

#### Construction of directional cDNA libraries

Poly (A)+ RNA from anti-CD3 stimulated  $\alpha\beta$ DN thymocytes or unstimulated abDN thymocytes was used to synthesize first strand cDNA by using NotI/Oligo-dT primer (Gibco-BRL, Gaithersburg, MD). Double-stranded cDNA was synthesized, 10 ligated with BstXI adaptors, digested with NotI, size fractionated for  $> 0.5$  kilobase pairs (kb) and ligated into the NotI/BstXI sites of pJFE-14, a derivative of the pCDSR $\alpha$  vector. See Takebe, et al. Mol. Cell Biol. 8:466-472.

15 Electro-competent E. coli DH10 $\alpha$  cells (Gibco-BRL) were used for transformation. Total number of independent clones of the cDNA libraries were  $1.2 \times 10^6$  for stimulated  $\alpha\beta$ DN and  $8 \times 10^5$  for unstimulated  $\alpha\beta$ DN thymocytes, respectively.

#### 20 Library subtraction

The PCR-based subtraction system developed by Wang and Brown (1991) Proc. Natl. Acad. Sci. USA 88:11505-11509, was modified to apply to plasmid cDNA libraries. A cDNA library specific for activated  $\alpha\beta$ DN thymocytes was 25 generated using 100  $\mu$ g of the unstimulated  $\alpha\beta$ DN cDNA library DNA digested with XbaI, NotI, and ScaI as driver DNA and 5  $\mu$ g of the stimulated  $\alpha\beta$ DN cDNA library DNA as tracer DNA. Following restriction digestion, the driver DNA was treated with DNA polymerase Klenow fragment to 30 fill-in the restriction sites. After ethanol precipitation, the DNA was dissolved in 100  $\mu$ l of water, heat-denatured and mixed with 100  $\mu$ l (100  $\mu$ g) of Photoprobe biotin (Vector Laboratories, Burlingame, CA). The driver DNA was then irradiated with a 270-W sunlamp on ice for 20 35 min. 50  $\mu$ l more Photoprobe biotin was added and the biotinylation reaction was repeated. After butanol extraction, the photobiotinylated DNA (driver-U) was

ethanol-precipitated and dissolved in 30  $\mu$ l of 10 mM Tris-HCl and 1 mM EDTA, pH 8 (TE). As tracer DNA, 5  $\mu$ g of stimulated  $\alpha\beta$ DN cDNA was digested with XbaI and NotI; ethanol precipitated; and dissolved in 4  $\mu$ l of TE (tracer-S). Tracer-S was mixed with 15  $\mu$ l of driver-U, 1  $\mu$ l (10  $\mu$ g) of E. coli tRNA (Sigma, St. Louis, MO), and 20  $\mu$ l of 2 x hybridization buffer (1.5 M NaCl, 10 mM EDTA, 50 mM HEPES, pH 7.5, 0.2% SDS), overlaid with mineral oil, and heat-denatured. The sample tube was immediately transferred into a 68° C water bath and incubated for 20 h. The reaction mixture was then subjected to streptavidin treatment followed by phenol/chloroform extraction. Subtracted DNA was precipitated, dissolved in 12  $\mu$ l of TE, mixed with 8  $\mu$ l of driver-U and 20  $\mu$ l of 2 x hybridization buffer, and then incubated at 68° C for 2 h. After streptavidin treatment, the remaining DNA was ligated with 250 ng of a purified XbaI / NotI fragment of pJFE-14 and then transformed into electro-competent E. coli cells to generate the activation specific  $\alpha\beta$ DN subtracted library (S1). 100 independent clones were randomly picked and screened by hybridization using a cocktail of known cytokine cDNAs. Plasmid DNA's were prepared from clones that did not hybridize to the cytokine probes. These clones were grouped by insert size and further characterized by DNA sequencing. Clones corresponding to the 312C2 were isolated.

## EXAMPLE 2: Cellular Expression of Mouse 312C2

A probe specific for cDNA encoding mouse 312C2 was used to determine tissue distribution of the antigen. All probes were labeled by random priming.

The results showed that 312C2 was expressed most abundantly in T cells, in particular, certain subsets of activated T cells. Thymus, spleen, and lymph node appeared to have more expression than other tissues. Expression levels are: thymus +; Th1 subset ++++; Th2 subset ++++, NK1.1+ T cells ++;  $\alpha\beta$  T cells ++; pro T cells +; CD4+ cells



++; CD8+ cells ++; and activated spleen cells +. A message was also detected in certain pro-, pre-, and mature B cell lines. The signal in the following cell types suggested that expression is very low to virtually absent in lung, heart, kidney, macrophage, stroma, brain, liver, muscle, and testes.

### EXAMPLE 3: Purification of 312C2 Protein

Multiple transfected cell lines are screened for one which expresses the antigen at a high level compared with other cells. Various cell lines are screened and selected for their favorable properties in handling. Natural 312C2 can be isolated from natural sources, or by expression from a transformed cell using an appropriate expression vector. Purification of the expressed protein is achieved by standard procedures, or may be combined with engineered means for effective purification at high efficiency from cell lysates or supernatants. FLAG or His<sub>6</sub> segments can be used for such purification features.

By Northern analysis, it is clear that 312C2 is expressed in various Th1, Th2, CD4+, CD8+, NK1.1+, pro-, pre-, and  $\alpha\beta$ CD4-CD8- T cells. 312C2 is also expressed in thymus and activated spleen cells. Cells expressing 312C2 typically contain a transcript of about 1.3 kb, corresponding to the size of the cloned 312C2 cDNA. Transcripts for 312C2 have not been detected in heart, kidney, macrophage, stroma, brain, liver, muscle, testes tissue.

The structural homology of 312C2 to the TNF receptor family, suggests a broad function of this molecule. 312C2, as an activation molecule, likely mediates enhanced Ag-specific proliferative responses on T cells, or induction of apoptosis of these cells. 312C2 agonists, or antagonists, may also act as a co-stimulatory molecule for T-cell activation, and may in fact, cause a shift of T helper cell types, e.g., from Th1 to Th2, or Th2 to Th1. Thus, 312C2 may be useful in the treatment of abnormal

immune disorders, e.g., T cell immune deficiencies, chronic inflammation, or tissue rejection.

The mouse 312C12 protein exhibits structural features characteristic of a cell surface antigen. The protein is easily detected on particular cell types, others express lesser amounts. The 312C2 antigen should be present in the identified tissue types and the interaction of the antigen with its binding partner should be important for mediating various aspects of cellular physiology or development.

10

#### EXAMPLE 4: Isolation of Homologous 312C2 Genes

The 312C2 cDNA can be used as a hybridization probe to screen a library from a desired source, e.g., a primate cell cDNA library. Many different species can be screened both for stringency necessary for easy hybridization, and for presence using a probe. Appropriate hybridization conditions will be used to select for clones exhibiting specificity of cross hybridization. Specifically, the mouse 312C2 cDNA clone was used to probe the HY06 human anergic T cell library. A clone of about 1006 bp encoding a predicted polypeptide of 241 amino acids was isolated.

Screening by hybridization using degenerate probes based upon the peptide sequences will also allow isolation of appropriate clones. Alternatively, use of appropriate primers for PCR screening will yield enrichment of appropriate nucleic acid clones. See SEQ ID NO: 5.

Similar methods are applicable to isolate either species, polymorphic, or allelic variants. Species variants are isolated using cross-species hybridization techniques based upon isolation of a full length isolate or fragment from one species as a probe.

Alternatively, antibodies raised against mouse 312C2 will be used to screen for cells which express cross-reactive proteins from an appropriate, e.g., cDNA library. The purified protein or defined peptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein are

presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press. The resulting antibodies are used for screening, panning, or sorting.

EXAMPLE 5: Expression and tissue distribution of human 312C2

Southern and PCR analysis of various hematopoietic cells and tissues was performed as described above. Expression was detected in several cell lines and tissues, most notably, stimulated dendritic cell library, some activated T cell clones, activated PBMCs, NK clones, Th1, Th2 cells, pre-T cells, pro-T cells. Spleen and lung tissue had detectable levels of 312C2.

EXAMPLE 6: Preparation of antibodies specific for 312C2

Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press. Polyclonal serum, or hybridomas may be prepared. In appropriate situations, the binding reagent is either labeled as described above, e.g., fluorescence or otherwise, or immobilized to a substrate for panning methods.

EXAMPLE 7: Chromosomal mapping of 312C2

Chromosome spreads are prepared. In situ hybridization is performed on chromosome preparations obtained from phytohemagglutinin-stimulated lymphocytes cultured for 72 h. 5-bromodeoxyuridine is added for the final seven hours of culture (60 µg/ml of medium), to ensure a posthybridization chromosomal banding of good quality.

An appropriate fragment, e.g., a PCR fragment, amplified with the help of primers on total B cell cDNA template, is cloned into an appropriate vector. The vector is labeled by nick-translation with  $^3\text{H}$ . The radiolabeled probe is hybridized to metaphase spreads as described in Mattei, et al. (1985) Hum. Genet. 69:327-331.

After coating with nuclear track emulsion (KODAK NTB2), slides are exposed, e.g., for 18 days at 4° C. To avoid any slipping of silver grains during the banding procedure, chromosome spreads are first stained with buffered Giemsa solution and metaphase photographed. R-banding is then performed by the fluorochrome-photolysis-Giemsa (FPG) method and metaphases rephotographed before analysis.

#### EXAMPLE 8: Isolation of variants from individuals

Mutational 312C2 variants from individuals having abnormal immune responses are isolated by standard methods. For example, affected cells, e.g., lymphocytes, are isolated as described, e.g., in Coligan (1991) Current Protocols in Immunology Wiley/Greene, NY. cDNA libraries are constructed as described above and probed with the mouse or human 312C2 clone. Isolated clones are then sequenced and compared to the human or mouse clone.

Alternatively, PCR techniques are also be employed to isolate variants. See, e.g., Innis, et al. (eds.) (1990) PCR Protocols: A Guide to Methods and Applications, Academic Press, N.Y.

#### EXAMPLE 9: Immunohistochemical localization

The antibody described in Example 6 is used to identify expression of 312C2 in various tissues. Methods for immunohistochemical staining are described, e.g., in Sheehan, et al. (eds.) (1987) Theory and Practice of Histotechnology, Battelle Press, Columbus, OH.

#### EXAMPLE 10: Soluble molecules

Soluble constructs of 312C2 are made, e.g., as described in Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology, Greene and Wiley,

5 NY; and Coligan, et al. (eds.) (1995 and periodic supplements) Current Protocols in Protein Science, John Wiley and Sons, NY. Briefly, the transmembrane portion of 312C2 is truncated. The nucleic acid encoding the remaining portions of the molecule is subcloned into an appropriate vector and the protein expressed through a  
10 suitable host cell.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific  
15 embodiments described above are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled. All references cited herein are incorporated herein by  
20 reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

SEQUENCE SUBMISSION

5 SEQ ID NO: 1 is a mouse 312C2 nucleic acid sequence.  
 SEQ ID NO: 2 is a mouse 312C2 amino acid sequence.  
 SEQ ID NO: 3 is a human 312C2 nucleic acid sequence.  
 SEQ ID NO: 4 is a human 312C2 amino acid sequence.  
 SEQ ID NO: 5 is a reverse translation sequence.  
 SEQ ID NO: 6 is clone A8 amino acid sequence.  
 10 SEQ ID NO: 7 is clone A5 amino acid sequence.  
 SEQ ID NO: 8 is clone G10 amino acid sequence.

SEQUENCE LISTING

15 (1) GENERAL INFORMATION:

(i) APPLICANT: Gorman, Daniel M.  
 Randall, Troy D.  
 Zlotnik, Albert

20 (ii) TITLE OF INVENTION: Mammalian Cell Surface Antigens; Related  
 Reagents

25 (iii) NUMBER OF SEQUENCES: 9

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: DNAX Research Institute  
 (B) STREET: 901 California Avenue  
 (C) CITY: Palo Alto  
 30 (D) STATE: California  
 (E) COUNTRY: USA  
 (F) ZIP: 94304-1104

35 (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

40 (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US Not yet assigned  
 (B) FILING DATE: August 14, 1997  
 (C) CLASSIFICATION:

45 (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 60/023,419  
 (B) FILING DATE: 16-AUG-1996

50 (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 60/027,901  
 (B) FILING DATE: 07-OCT-1996

55 (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Ching, Edwin P.  
 (B) REGISTRATION NUMBER: 34,090  
 (C) REFERENCE/DOCKET NUMBER: DX0612K1

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE:  
 60 (B) TELEFAX:

## (2) INFORMATION FOR SEQ ID NO:1:

- 5 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1073 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: cDNA

- 15 (ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 68..754  
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

20 CTCGAGATCC ATTGTGCTGG AAAGGGAACCT CCTGAAATCA GCCGACAGAA GACTCAGGAG 60  
 AAGCACT ATG GGG GCA TGG GCC ATG CTG TAT GGA GTC TCG ATG CTC TGT 109  
 Met Gly Ala Trp Ala Met Leu Tyr Gly Val Ser Met Leu Cys  
 25 1 5 10  
 GTG CTG GAC CTA GGT CAG CCG AGT GTA GTT GAG GAG CCT GGC TGT GGC 157  
 Val Leu Asp Leu Gly Gln Pro Ser Val Val Glu Glu Pro Gly Cys Gly  
 15 20 25 30  
 30 CCT GGC AAG GTT CAG AAC GGA AGT GGC AAC AAC ACT CGC TGC TGC AGC 205  
 Pro Gly Lys Val Gln Asn Gly Ser Gly Asn Asn Thr Arg Cys Cys Ser  
 35 35 40 45  
 CTG TAT GCT CCA GGC AAG GAG GAC TGT CCA AAA GAA AGG TGC ATA TGT 253  
 Leu Tyr Ala Pro Gly Lys Glu Asp Cys Pro Lys Glu Arg Cys Ile Cys  
 50 55 60  
 40 GTC ACA CCT GAG TAC CAC TGT GGA GAC CCT CAG TGC AAG ATC TGC AAG 301  
 Val Thr Pro Glu Tyr His Cys Gly Asp Pro Gln Cys Lys Ile Cys Lys  
 65 70 75  
 CAC TAC CCC TGC CAA CCA GGC CAG AGG GTG GAG TCT CAA GGC GAT ATT 349  
 His Tyr Pro Cys Gln Pro Gly Gln Arg Val Glu Ser Gln Gly Asp Ile  
 45 80 85 90  
 GTG TTT GGC TTC CGG TGT GTT GCC TGT GCC ATG GGC ACC TTC TCC GCA 397  
 Val Phe Gly Phe Arg Cys Val Ala Cys Ala Met Gly Thr Phe Ser Ala  
 95 100 105 110  
 50 GGT CGT GAC GGT CAC TGC AGA CTT TGG ACC AAC TGT TCT CAG TTT GGA 445  
 Gly Arg Asp Gly His Cys Arg Leu Trp Thr Asn Cys Ser Gln Phe Gly  
 115 120 125  
 55 TTT CTC ACC ATG TTC CCT GGG AAC AAG ACC CAC AAT GCT GTG TGC ATC 493  
 Phe Leu Thr Met Phe Pro Gly Asn Lys Thr His Asn Ala Val Cys Ile  
 130 135 140  
 60 CCG GAG CCA CTG CCC ACT GAG CAA TAC GGC CAT TTG ACT GTC ATC TTC 541  
 Pro Glu Pro Leu Pro Thr Glu Gln Tyr Gly His Leu Thr Val Ile Phe

145 150 155

5 CTG GTC ATG GCT GCA TGC ATT TTC TTC CTA ACC ACA GTC CAG CTC GGC 589  
 Leu Val Met ala Ala Cys Ile Phe Phe Leu Thr Thr Val Gln Leu Gly  
 160 165 170

10 CTG CAC ATA TGG CAG CTG AGG AGG CAA CAC ATG TGT CCC CGA GAG ACC 637  
 Leu His Ile Trp Gln Leu Arg Arg Gln His Met Cys Pro Arg Glu Thr  
 175 180 185 190

CAG CCA TTC GCG GAG GTG CAG TTG TCA GCT GAG GAT GCT TGC AGC TTC 685  
 Gln Pro Phe Ala Glu Val Gln Leu Ser Ala Glu Asp Ala Cys Ser Phe  
 195 200 205

15 CAG TTC CCT GAG GAG GAA CGC GGG GAG CAG ACA GAA GAA AAG TGT CAT 733  
 Gln Phe Pro Glu Glu Glu Arg Gly Glu Gln Thr Glu Glu Lys Cys His  
 210 215 220

20 CTG GGG GGT CGG TGG CCA TGAGGCCTGG TCTTCCTCTG TGCCCCAAGC 781  
 Leu Gly Gly Arg Trp Pro  
 225

CAGACGCTAC AAGACTTGCC CAGCTATAACC CTTGGTGAGA GCAGGGGCCA TGCTCTGCAC 841

25 CCTTCCCTGG GCCTGGCCCT GCTCCCCTCA ACAGTGCGCG AAGTGGGTGT ATGAGAGCGG 901

TGAGTTACGA TTGGGCCCTA TGGCTGCCTT TCTCATTTGA CAGCTCTGTT GGAGTAGGGT 961

CTTTGGGCCC ACCAAGAGCA CCACGTTTAG CACAAGATCT TGTACAAGAA TAAATACTTG 1021

30 TTTAGTAACC TGAAAAAAAA AAAAAAAGG GCGGCCGCGG AGGCCGAATT CC 1073

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 228 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Gly Ala Trp Ala Met Leu Tyr Gly Val Ser Met Leu Cys Val Leu  
 1 5 10 15

45 Asp Leu Gly Gln Pro Ser Val Val Glu Glu Pro Gly Cys Gly Pro Gly  
 20 25 30

Lys Val Gln Asn Gly Ser Gly Asn Asn Thr Arg Cys Cys Ser Leu Tyr  
 35 40 45

Ala Pro Gly Lys Glu Asp Cys Pro Lys Glu Arg Cys Ile Cys Val Thr  
 50 55 60

55 Pro Glu Tyr His Cys Gly Asp Pro Gln Cys Lys Ile Cys Lys His Tyr  
 65 70 75 80

Pro Cys Gln Pro Gly Gln Arg Val Glu Ser Gln Gly Asp Ile Val Phe  
 85 90 95

60



Gly Phe Arg Cys Val Ala Cys Ala Met Gly Thr Phe Ser Ala Gly Arg  
 100 105 110  
 5 Asp Gly His Cys Arg Leu Trp Thr Asn Cys Ser Gln Phe Gly Phe Leu  
 115 120 125  
 Thr Met Phe Pro Gly Asn Lys Thr His Asn Ala Val Cys Ile Pro Glu  
 130 135 140  
 10 Pro Leu Pro Thr Glu Gln Tyr Gly His Leu Thr Val Ile Phe Leu Val  
 145 150 155 160  
 Met Ala Ala Cys Ile Phe Phe Leu Thr Thr Val Gln Leu Gly Leu His  
 165 170 175  
 15 Ile Trp Gln Leu Arg Arg Gln His Met Cys Pro Arg Glu Thr Gln Pro  
 180 185 190  
 Phe Ala Glu Val Gln Leu Ser Ala Glu Asp Ala Cys Ser Phe Gln Phe  
 195 200 205  
 Pro Glu Glu Glu Arg Gly Glu Gln Thr Glu Glu Lys Cys His Leu Gly  
 210 215 220  
 25 Gly Arg Trp Pro  
 225

(2) INFORMATION FOR SEQ ID NO:3:

30 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1006 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:  
 40 (A) NAME/KEY: CDS  
 (B) LOCATION: 1..723

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

45 ATG GCA CAG CAC GGG GCG ATG GGC GCG TTT CGG GCC CTG TGC GGC CTG 48  
 Met Ala Gln His Gly Ala Met Gly Ala Phe Arg Ala Leu Cys Gly Leu  
 1 5 10 15  
 50 GCG CTG CTG TGC GCG CTC AGC CTG GGT CAG CGC CCC ACC GGG GGT CCC 96  
 Ala Leu Leu Cys Ala Leu Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro  
 20 25 30  
 55 GGG TGC GGC CCT GGG CGC CTC CTG CTT GGG ACG GGA ACG GAC GCG CGC 144  
 Gly Cys Gly Pro Gly Arg Leu Leu Gly Thr Gly Thr Asp Ala Arg  
 35 40 45  
 TGC TGC CGG GTT CAC ACG ACG CGC TGC TGC CGC GAT TAC CCG GGC GAG 192  
 Cys Cys Arg Val His Thr Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu  
 50 55 60

	GAG TGC TGT TCC GAG TGG GAC TGC ATG TGT GTC CAG CCT GAA TTC CAC	240
	Glu Cys Cys Ser Glu Trp Asp Cys Met Cys Val Gln Pro Glu Phe His	
	65 70 75 80	
5	TGC GGA GAC CCT TGC TGC ACG ACC TGC CGG CAC CAC CCT TGT CCC CCA	288
	Cys Gly Asp Pro Cys Cys Thr Thr Cys Arg His His Pro Cys Pro Pro	
	85 90 95	
10	GGC CAG GGG GTA CAG TCC CAG GGG AAA TTC AGT TTT GGC TTC CAG TGT	336
	Gly Gln Gly Val Gln Ser Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys	
	100 105 110	
15	ATC GAC TGT GCC TCG GGG ACC TTC TCC GGG GGC CAC GAA GGC CAC TGC	384
	Ile Asp Cys Ala Ser Gly Thr Phe Ser Gly Gly His Glu Gly His Cys	
	115 120 125	
20	AAA CCT TGG ACA GAC TGC ACC CAG TTC GGG TTT CTC ACT GTG TTC CCT	432
	Lys Pro Trp Thr Asp Cys Thr Gln Phe Gly Phe Leu Thr Val Phe Pro	
	130 135 140	
25	GGG AAC AAG ACC CAC AAC GCT GTG TGC GTC CCA GGG TCC CCG CCG GCA	480
	Gly Asn Lys Thr His Asn Ala Val Cys Val Pro Gly Ser Pro Pro Ala	
	145 150 155 160	
30	GAG CCG CTT GGG TGG CTG ACC GTC GTC CTC CTG GCC GTG GCC GCC TGC	528
	Glu Pro Leu Gly Trp Leu Thr Val Val Leu Leu Ala Val Ala Ala Cys	
	165 170 175	
35	GTC CTC CTC CTG ACC TCG GCC CAG CTT GGA CTG CAC ATC TGG CAG CTG	576
	Val Leu Leu Leu Thr Ser Ala Gln Leu Gly Leu His Ile Trp Gln Leu	
	180 185 190	
40	AGG AGT CAG TGC ATG TGG CCC CGA GAG ACC CAG CTG CTG CTG GAG GTG	624
	Arg Ser Gln Cys Met Trp Pro Arg Glu Thr Gln Leu Leu Leu Glu Val	
	195 200 205	
45	CCG CCG TCG ACC GAA GAC GCC AGA AGC TGC CAG TTC CCC GAG GAA GAG	672
	Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro Glu Glu Glu	
	210 215 220	
50	CGG GGC GAG CGA TCG GCA GAG GAG AAG GGG CGG CTG GGA GAC CTG TGG	720
	Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly Asp Leu Trp	
	225 230 235 240	
55	GTG TGAGCCTGGC CGTCCTCCGG GGCCACCGAC CGCAGCCAGC CCCTCCCCAG	773
	Val	
60	GAGCTCCCCA GGCCGCAGGG GCTCTGCGTT CTGCTCTGGG CCGGGCCCTG CTCCCCTGGC	833
	AGCAGAAGTG GGTGCAGGAA GGTGGCAGTG ACCAGCGCCC TGGACCATGC AGTTCGGCGG	893
	CCGCTCTAAA GGATCCAAGC TTACGTACGC GTGCATGCGA CGTCATAGCT CTTCTATAGT	953
	GTCACCTAAA TTCAATTCAC TGGCCGTCGT TTTACAACGT CCTGACTGGG AAA	1006

(2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 241 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

10 Met Ala Gln His Gly Ala Met Gly Ala Phe Arg Ala Leu Cys Gly Leu  
1 5 10 15  
Ala Leu Leu Cys Ala Leu Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro  
20 25 30  
15 Gly Cys Gly Pro Gly Arg Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg  
35 40 45  
20 Cys Cys Arg Val His Thr Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu  
50 55 60  
Glu Cys Cys Ser Glu Trp Asp Cys Met Cys Val Gln Pro Glu Phe His  
65 70 75 80  
25 Cys Gly Asp Pro Cys Cys Thr Thr Cys Arg His His Pro Cys Pro Pro  
85 90 95  
Gly Gln Gly Val Gln Ser Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys  
100 105 110  
30 Ile Asp Cys Ala Ser Gly Thr Phe Ser Gly Gly His Glu Gly His Cys  
115 120 125  
35 Lys Pro Trp Thr Asp Cys Thr Gln Phe Gly Phe Leu Thr Val Phe Pro  
130 135 140  
Gly Asn Lys Thr His Asn Ala Val Cys Val Pro Gly Ser Pro Pro Ala  
145 150 155 160  
40 Glu Pro Leu Gly Trp Leu Thr Val Val Leu Leu Ala Val Ala Ala Cys  
165 170 175  
Val Leu Leu Leu Thr Ser Ala Gln Leu Gly Leu His Ile Trp Gln Leu  
180 185 190  
45 Arg Ser Gln Cys Met Trp Pro Arg Glu Thr Gln Leu Leu Leu Glu Val  
195 200 205  
50 Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro Glu Glu Glu  
210 215 220  
Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly Asp Leu Trp  
225 230 235 240  
55 Val

(2) INFORMATION FOR SEQ ID NO:5:

60

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 723 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGGCNCARC AYGGNGCNAT GGGNGCNTTY MGNGCNYTNT GYGGNYTNGC NYTNYTNTGY 60  
 GCNYTNWSNY TGGNCARMG NCCNACNGGN GGNCNGGNT GYGGNCCNGG NMGNYYTNYTN 120  
 YTNNGNACNG GNACNGAYGC NMGNTGYTGY MGNGTNCAYA CNACNMGNTG YTGyMGNGAY 180  
 TAYCCNGGNG ARGARTGYTG YWSNGARTGG GAYTGYATGT GYGTNCARCC NGARTTYCAY 240  
 TGYGGNGAYC CNTGYTGYAC NACNTGYMGN CAYCAYCCNT GYCCNCCNGG NCARGGNGTN 300  
 CARWSNCARG GNAARTTYWS NTTYGGNTTY CARTGYATHG AYTGYGCNWS NGGNACNTTY 360  
 WSNGGNGGNC AYGARGGNA YTGyAARCCN TGGACNGAYT GYACNCARTT YGGNTTYTNY 420  
 ACNGTNTTYC CNGGNAAYAA RACNCAYAA Y GCNGTNTGYG TNCCNGGNWS NCCNCCNGCN 480  
 GARCCNYTNG GNTGGYTNAC NGTNGTNYTN YTNGCNGTNG CNGCNTGYGT NYTNYTNYTN 540  
 ACNWSNGCNC ARYTNGGNYT NCAYATHTGG CARYTNMGW SNCARTGYAT GTGGCCNMGN 600  
 GARACNCARY TNYTNYTNGA RGTNCCNCCN WSNACNGARG AYGCNMGNWS NTGYCARTTY 660  
 CCNGARGARG ARMGNGGNGA RMGNWSNGCN GARGARAARG GNMGNYTNGG NGAYYTNTGG 720  
 GTN 723

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 228 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Gly Ala Phe Arg Ala Leu Cys Gly Leu Ala Leu Leu Cys Ala Leu  
 1 5 10 15  
 Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro Gly Cys Gly Pro Gly Arg  
 20 25 30

Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg Cys Cys Arg Val His Thr  
 35 40 45  
 Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu Glu Cys Cys Ser Glu Trp  
 5 50 55 60  
 Asp Cys Met Cys Val Gln Pro Glu Phe His Cys Gly Asp Pro Cys Cys  
 65 70 75 80  
 Thr Thr Cys Arg His His Pro Cys Pro Pro Gly Gln Gly Val Gln Ser  
 10 85 90 95  
 Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys Ile Asp Cys Ala Ser Gly  
 100 105 110  
 Thr Phe Ser Gly Gly His Glu Gly His Cys Lys Pro Trp Thr Asp Cys  
 115 120 125  
 Thr Gln Phe Gly Phe Leu Thr Val Phe Pro Gly Asn Lys Thr His Asn  
 130 135 140  
 Ala Val Cys Val Pro Gly Ser Pro Pro Ala Glu Pro Leu Gly Trp Leu  
 145 150 155 160  
 Thr Val Val Leu Leu Ala Val Ala Ala Cys Val Leu Leu Leu Thr Ser  
 165 170 175  
 Ala Gln Leu Gly Leu His Ile Trp Gln Leu Arg Lys Thr Gln Leu Leu  
 180 185 190  
 Leu Glu Val Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro  
 195 200 205  
 Glu Glu Glu Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly  
 210 215 220  
 Asp Leu Trp Val  
 225

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 232 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Gly Ala Phe Arg Ala Leu Cys Gly Leu Ala Leu Leu Cys Ala Leu  
 1 5 10 15  
 Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro Gly Cys Gly Pro Gly Arg  
 20 25 30

[illegible]

40 (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 311 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

55 Met Gly Ala Phe Arg Ala Leu Cys Gly Leu Ala Leu Leu Cys Ala Leu  
1 5 10 15  
Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro Gly Cys Gly Pro Gly Arg  
20 25 30  
60

[illegible]

## WHAT IS CLAIMED IS:

1. A substantially pure or recombinant 312C2 protein or  
5 conservatively modified variants thereof, said protein:
  - a) is expressed on activated T cells; or
  - b) specifically binds to antibodies generated against  
SEQ ID NO: 2 or 4.
- 10 2. A protein or peptide of Claim 1, selected from the  
group consisting of:
  - a) a natural protein from a warm blooded animal  
selected from the group of birds and mammals,  
including a rodent or primate;
  - 15 b) a protein or peptide:
    - i) comprising at least one polypeptide segment  
of at least 14 amino acids of SEQ ID NO: 2;
    - ii) comprising at least one polypeptide segment  
of at least 14 amino acids of SEQ ID NO: 4;
    - 20 or
    - iii) which is not glycosylated;
    - iv) which is in a buffered solution;
    - v) which is attached to a solid substrate;
    - vi) which exhibits a plurality of epitopes from  
25 SEQ ID NO: 2 or 4;
    - vii) which is detectably labeled;
    - viii) which is a synthetic polypeptide;
    - ix) which is conjugated to a chemical moiety;
    - x) which is a 5-fold or less substitution from a  
30 natural sequence; or
    - xi) which is a deletion or insertion variant  
from a natural sequence.
3. A protein or peptide of Claim 1, comprising a sequence  
35 from the extracellular or the intracellular portion of a  
312C2.



4. A fusion protein comprising a peptide of Claim 1.

5. A sterile composition comprising the protein of Claim 1, and a pharmaceutically acceptable carrier.

5

6. An antibody which specifically binds a protein or peptide of Claim 1.

7. An antibody of Claim 6, wherein:

10

a) said 312C2 is a mammalian protein, including a mouse or human;

b) said antibody is raised against a purified peptide sequence of SEQ ID NO: 2 or 4;

c) said antibody is a monoclonal antibody;

15

d) said antibody is detectably labeled;

e) said antibody is attached to a solid substrate;

f) said antibody is in a sterile composition; or

g) said antibody is in a buffered composition.

20

8. A method of purifying a 312C2 protein or peptide from other materials in a mixture comprising contacting said mixture to an antibody of Claim 6, and separating bound 312C2 from other materials.

25

9. An isolated or recombinant nucleic acid capable of encoding a protein or peptide of Claim 1.

10. A nucleic acid of Claim 9, wherein said nucleic acid:

a) encodes a sequence of SEQ ID NO: 2 or 4;

30

b) comprises a sequence of SEQ ID NO: 1 or 3; or

c) encodes a sequence from an extracellular domain of a natural 312C2;

d) encodes a sequence from an intracellular domain of a natural 312C2;

35

e) attached to a solid substrate;

f) is detectable labeled; or

g) is in a sterile composition.

11. An expression or replicating vector of Claim 9.
12. A kit comprising:
  - 5 a) a substantially pure 312C2 or fragment of Claim 1;
  - b) an antibody or receptor which specifically binds a 312C2; or
  - c) a nucleic acid encoding a 312C2 or peptide.
- 10 13. A method for detecting in a sample the presence of a 312C2 nucleic acid, protein, or antibody, comprising testing said sample with a kit of Claim 12.
14. A method of modulating the physiology of a cell  
15 comprising contacting said cell with:
  - a) a substantially pure 312C2 or fragment of Claim 1;
  - b) an antibody or binding partner which specifically binds a 312C2; or
  - c) a nucleic acid encoding a 312C2 or peptide.
- 20 15. The method of Claim 14, wherein said cell is a T cell and said modulating of physiology is:
  - a) apoptosis of said T cell; or
  - b) activation of said T cell
- 25 16. A method of Claim 14, wherein said cell is in a tissue and/or in an organism.
17. A method of expressing a 312C2 comprising expressing a  
30 nucleic acid of Claim 9.
18. A cell, tissue, organ, or organism comprising a nucleic acid of Claim 9.
- 35 19. A recombinant nucleic acid comprising sequence at least about 70% identity over a stretch of at least about

30 nucleotides to a 312C2 nucleic acid sequence of SEQ ID NO: 1 or 3.

20. A nucleic acid of Claim 19, further encoding a polypeptide comprising at least about 60% identity over a stretch of at least about 20 amino acids to a 312C2 sequence of SEQ ID NO: 2 or 4.

21. A method of treating a host mammal having an abnormal immune response by administering to said mammal an effective dose of:

- a) an antibody or binding partner which binds specifically to a 312C2;
- b) a substantially pure 312C2 protein or peptide thereof; or
- c) a nucleic acid encoding a 312C2 peptide.

22. The method of Claim 21, wherein said abnormal immune response is characterized by:

- a) a T-cell immune deficiency;
- b) chronic inflammation; or
- c) tissue rejection.

## MAMMALIAN CELL SURFACE ANTIGENS; RELATED REAGENTS

## ABSTRACT

5        Purified genes encoding a T cell surface antigen from  
a mammal, reagents related thereto including purified  
proteins, specific antibodies, and nucleic acids encoding  
this antigen are provided. Methods of using said reagents  
and diagnostic kits are also provided.

10

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Daniel M. GORMAN, et al.

Serial No.: to be assigned

Filed: April 10, 2000

For: MAMMALIAN CELL SURFACE  
ANTIGENS; RELATED REAGENTS

Examiner: not assigned

Art Unit: not assigned

USE OF PRIOR OATH UNDER 37 CFR  
§1.63(d)

Palo Alto, California 94304

April 10, 2000

5

Assistant Commissioner for Patents  
Box: Patent Application  
Washington, D.C. 20231

10 Sir:

USE OF PRIOR OATH UNDER 37 CFR §1.63(d)

15 The enclosed copy of the oath/declaration is for the  
attached application submitted herewith. Since the present  
application is a divisional application filed by all of the  
inventors from the originally filed application (USSN  
08/911,423; filed August 14, 1997) a newly executed oath or  
declaration is not required as specified under 37 CFR §1.63(d)  
20 as long as a copy of the signed oath or declaration filed in the  
prior application is submitted. Accordingly, please use the  
enclosed copy oath/declaration for the current application.

25

Respectfully submitted,

Dated: April 7, 2000By: Edwin P. ChingEdwin P. Ching  
Attorney for Applicants  
Reg. No. 34,090

30

DNAX Research Institute  
901 California Avenue  
Palo Alto, California 94304-1104  
35 Tel: (650) 852-9196  
Fax: (650) 496-1200

DECLARATION AND POWER OF  
ATTORNEY FOR PATENT APPLICATION

Attorney's Docket No. DX0612K1

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"MAMMALIAN CELL SURFACE ANTIGENS: RELATED REAGENTS"

the specification of which

☐ is attached hereto.

☒ was filed on August 14, 1997 as Application Serial No. 08/911,423

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):	Priority Claimed		
(Number)	(Country)	(Day/Month/Year Filed)	Yes or No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

<u>60/023,419</u> (Application Number)	<u>August 16, 1996</u> (Filing Date)
<u>60/027,901</u> (Application Number)	<u>October 7, 1996</u> (Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status - patented, pending, abandoned)

Daniel M. GORMAN, et al., USSN No.: 08/911,423  
Filed: August 14, 1997

Power of Attorney: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in Patent and Trademark Office connected therewith. (List name and registration number.)

Carl W. Battle	Reg. No. 30,731	Anita W. Magatti	Reg. No. 29,825
Edwin P. Ching	Reg. No. 34,090	John J. Maitner	Reg. No. 25,636
Eric S. Dicker	Reg. No. 31,699	Joseph T. Majka	Reg. No. 30,570
Norman C. Dulak	Reg. No. 31,608	Arthur Mann	Reg. No. 35,598
Cynthia L. Foulke	Reg. No. 32,364	Edward H. Mazer	Reg. No. 27,573
Robert A. Franks	Reg. No. 28,605	Jaye P. McLaughlin	Reg. No. 41,211
James M. Gould	Reg. No. 33,702	Richard B. Murphy	Reg. No. 35,298
Richard J. Grochala	Reg. No. 31,518	James R. Nelson	Reg. No. 27,929
Thomas D. Hoffman	Reg. No. 28,221	Immac J. Thampoe	Reg. No. 36,322
Henry C. Jeanette	Reg. No. 30,856	Paul A. Thompson	Reg. No. 35,385
Susan Lee	Reg. No. 30,653		




Send Correspondence to:  Edwin P. Ching DNAX Research Institute 901 California Avenue Palo Alto, CA 94304-1104	Direct Telephone Calls to:  Name: Edwin P. Ching Telephone No.: (650) 496-1204 Facsimile No.: (650) 496-1200
---	--

FULL NAME OF 1ST OR SOLE INVENTOR	FAMILY NAME Gorman	FIRST GIVEN NAME Daniel	SECOND GIVEN NAME M.
RESIDENCE & CITIZENSHIP	CITY Newark	STATE OR FOREIGN COUNTRY CA	COUNTRY OF CITIZENSHIP U.S.A.
POST OFFICE ADDRESS	POST OFFICE ADDRESS 6371 Central Avenue	CITY Newark	STATE & ZIP CODE/COUNTRY CA 94560 / U.S.A.

FULL NAME OF 2ND JOINT INVENTOR	FAMILY NAME Randall	FIRST GIVEN NAME Troy	SECOND GIVEN NAME D.
RESIDENCE & CITIZENSHIP	CITY Saranac Lake	STATE OR FOREIGN COUNTRY NY	COUNTRY OF CITIZENSHIP U.S.A.
POST OFFICE ADDRESS	POST OFFICE ADDRESS 100 Algonquin Avenue P.O. Box 59	CITY Saranac Lake	STATE & ZIP CODE/COUNTRY NY 12983 / U.S.A.

FULL NAME OF 3RD JOINT INVENTOR	FAMILY NAME Zlotnik	FIRST GIVEN NAME Albert	SECOND GIVEN NAME
RESIDENCE & CITIZENSHIP	CITY Palo Alto	STATE OR FOREIGN COUNTRY CA	COUNTRY OF CITIZENSHIP U.S.A.
POST OFFICE ADDRESS	POST OFFICE ADDRESS 507 Alger Drive	CITY Palo Alto	STATE & ZIP CODE/COUNTRY CA 94306 / U.S.A.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of First Inventor  Daniel M. Gorman	Signature of Second Inventor  Troy D. Randall	Signature of Third Inventor  Albert Zlotnik
Date 11/14/97	Date Nov 7, 1997	Date Nov 17, 1997



I hereby certify that .s correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX MISSING PARTS, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 on the date indicated below.

January 28, 1998

By:

Lois E. Miller

PATENT/DX0612K1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Daniel M, GORMAN, et al.

Serial No.: 08/911,423

Filed: August 14, 1997

For: MAMMALIAN CELL SURFACE  
ANTIGENS; RELATED REAGENTS

Examiner: not yet assigned

Art Unit: 1815

COMPUTER READABLE SEQUENCE  
SUBMISSION

Palo Alto, California 94304

January 28, 1998

5 Box: Missing Parts  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

10 COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES

15 In anticipation of a "Notice to Comply" requiring  
compliance with requirements for patent applications containing  
nucleotide sequence and/or amino acid sequence disclosures, for  
the above-identified application, in accordance with 37 CFR §  
1.821 - 1.825, Applicants hereby submit: (1) a write-protected  
20 diskette containing a computer-readable submission for the  
"Sequence Listing"; (2) a "Sequence Listing" paper copy of the  
contents of the diskette; and (3) a preliminary amendment  
inserting the newly submitted sequence listing into the  
Specification.

## AMENDMENTS

### IN THE SPECIFICATION

5 Please delete originally submitted pages 63-72 and  
substitute therefor new pages numbered 63-73 (11 sheets) which  
are attached hereto. Please renumber the following pages:  
Original page 73 as page 74; original page 74 as page 75;  
original page 75 as page 76; original page 76 as page 77; and  
10 original page 77 as page 78.

### REMARKS

Applicants amend the Specification to incorporate a  
Sequence Listing. No new matter is added herein, as these  
15 sequences were all included in the original filing documents.  
New pages 63-73 (11 sheets) are attached hereto for insertion  
into the Specification.

Also enclosed is a write protected floppy diskette with the  
sequence listing generated by the Patent Office's PATENTIN  
20 program. The Diskette should comply with the requirements of 37  
CFR §1.824 and is IBM PC compatible with a PC-DOS/MS-DOS  
operating system. If the diskette has been damaged, please call  
Applicants and a replacement diskette will be provided. A hard  
paper copy printout of the diskette is attached thereto.

25 I hereby state the informational contents of the paper and  
computer readable copies of the Sequence Listing, submitted in  
accordance with 37 CFR 1.821(c) and (e), respectively, are  
believed to be the same. This submission introduces no new  
matter, since enclosed sequences are the same as sequences which  
30 were submitted in priority documents.

Applicants have invested over two hours of significant labor and care in preparing the present submission. The enclosed items are a bona fide effort to bring the present application into full compliance with the rules for sequence  
5 submissions. Should this not be the case, Applicants respectfully request notification of specific deficiencies and an opportunity for remedy, as described in 37 CFR 1.135(c).

Applicants believe that no fees are required; however, if any fees are required by the present Response, the Commissioner  
10 is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

15 Dated: January 28, 1998

By: Edwin P. Ching  
Edwin P. Ching  
Reg. No. 34,090

20 enclosures and attachments:  
new pages 54-67 (14 sheets)  
one write-protected diskette (CRM)  
paper copy of contents of diskette

25 DNAX Research Institute  
901 California Avenue  
Palo Alto, California 94304-1104  
Tel: 650-852-9196  
30 Fax: 650-496-1200

## SEQUENCE LISTING

SEQ ID NO: 1 is a mouse 312C2 nucleic acid sequence.  
SEQ ID NO: 2 is a mouse 312C2 amino acid sequence.  
5 SEQ ID NO: 3 is a human 312C2 nucleic acid sequence.  
SEQ ID NO: 4 is a human 312C2 amino acid sequence.  
SEQ ID NO: 5 is a reverse translation sequence.  
SEQ ID NO: 6 is clone A8 amino acid sequence.  
SEQ ID NO: 7 is clone A5 amino acid sequence.  
10 SEQ ID NO: 8 is clone G10 amino acid sequence.

## (1) GENERAL INFORMATION:

(i) APPLICANT: Gorman, Daniel M.  
15 Randall, Troy D.  
Zlotnik, Albert

(ii) TITLE OF INVENTION: MAMMALIAN CELL SURFACE ANTIGENS; RELATED  
20 REAGENTS

(iii) NUMBER OF SEQUENCES: 8

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: DNAX Research Institute  
25 (B) STREET: 901 California Avenue  
(C) CITY: Palo Alto  
(D) STATE: California  
(E) COUNTRY: USA  
30 (F) ZIP: 94304-1104

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
35 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/911,423  
(B) FILING DATE: 14-AUG-1997  
40 (C) CLASSIFICATION:

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 60/023,419  
45 (B) FILING DATE: 16-AUG-1996

## (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 60/027,901  
50 (B) FILING DATE: 07-OCT-1996

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Ching, Edwin P.  
(B) REGISTRATION NUMBER: 34,090  
(C) REFERENCE/DOCKET NUMBER: DX0612K

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 650-852-9196  
55 (B) TELEFAX: 650-496-1200

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1073 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- 15 (A) NAME/KEY: CDS  
(B) LOCATION: 68..751

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

20 CTCGAGATCC ATTGTGCTGG AAAGGGAACCT CCTGAAATCA GCCGACAGAA GACTCAGGAG 60  
AAGCACT ATG GGG GCA TGG GCC ATG CTG TAT GGA GTC TCG ATG CTC TGT 109  
Met Gly Ala Trp Ala Met Leu Tyr Gly Val Ser Met Leu Cys  
1 5 10  
25 GTG CTG GAC CTA GGT CAG CCG AGT GTA GTT GAG GAG CCT GGC TGT GGC 157  
Val Leu Asp Leu Gly Gln Pro Ser Val Val Glu Glu Pro Gly Cys Gly  
15 20 25 30  
30 CCT GGC AAG GTT CAG AAC GGA AGT GGC AAC AAC ACT CGC TGC TGC AGC 205  
Pro Gly Lys Val Gln Asn Gly Ser Gly Asn Asn Thr Arg Cys Cys Ser  
35 40 45  
35 CTG TAT GCT CCA GGC AAG GAG GAC TGT CCA AAA GAA AGG TGC ATA TGT 253  
Leu Tyr Ala Pro Gly Lys Glu Asp Cys Pro Lys Glu Arg Cys Ile Cys  
50 55 60  
40 GTC ACA CCT GAG TAC CAC TGT GGA GAC CCT CAG TGC AAG ATC TGC AAG 301  
Val Thr Pro Glu Tyr His Cys Gly Asp Pro Gln Cys Lys Ile Cys Lys  
65 70 75  
CAC TAC CCC TGC CAA CCA GGC CAG AGG GTG GAG TCT CAA GGG GAT ATT 349  
His Tyr Pro Cys Gln Pro Gly Gln Arg Val Glu Ser Gln Gly Asp Ile  
80 85 90  
45 GTG TTT GGC TTC CGG TGT GTT GCC TGT GCC ATG GGC ACC TTC TCC GCA 397  
Val Phe Gly Phe Arg Cys Val Ala Cys Ala Met Gly Thr Phe Ser Ala  
95 100 105 110  
50 GGT CGT GAC GGT CAC TGC AGA CTT TGG ACC AAC TGT TCT CAG TTT GGA 445  
Gly Arg Asp Gly His Cys Arg Leu Trp Thr Asn Cys Ser Gln Phe Gly  
115 120 125  
TTT CTC ACC ATG TTC CCT GGG AAC AAG ACC CAC AAT GCT GTG TGC ATC 493  
Phe Leu Thr Met Phe Pro Gly Asn Lys Thr His Asn Ala Val Cys Ile  
130 135 140

5 CCG GAG CCA CTG CCC ACT GAG CAA TAC GGC CAT TTG ACT GTC ATC TTC 541  
 Pro Glu Pro Leu Pro Thr Glu Gln Tyr Gly His Leu Thr Val Ile Phe  
 145 150 155  
 10 CTG GTC ATG GCT GCA TGC ATT TTC TTC CTA ACC ACA GTC CAG CTC GGC 589  
 Leu Val Met Ala Ala Cys Ile Phe Phe Leu Thr Thr Val Gln Leu Gly  
 160 165 170  
 15 CTG CAC ATA TGG CAG CTG AGG AGG CAA CAC ATG TGT CCC CGA GAG ACC 637  
 Leu His Ile Trp Gln Leu Arg Arg Gln His Met Cys Pro Arg Glu Thr  
 175 180 185 190  
 20 CAG CCA TTC GCG GAG GTG CAG TTG TCA GCT GAG GAT GCT TGC AGC TTC 685  
 Gln Pro Phe Ala Glu Val Gln Leu Ser Ala Glu Asp Ala Cys Ser Phe  
 195 200 205  
 25 CAG TTC CCT GAG GAG GAA CGC GGG GAG CAG ACA GAA GAA AAG TGT CAT 733  
 Gln Phe Pro Glu Glu Glu Arg Gly Glu Gln Thr Glu Glu Lys Cys His  
 210 215 220  
 30 CTG GGG GGT CGG TGG CCA TGAGGCCTGG TCTTCCTCTG TGCCCCAAGC 781  
 Leu Gly Gly Arg Trp Pro  
 225  
 35 CAGACGCTAC AAGACTTGCC CAGCTATAACC CTTGGTGAGA GCAGGGGCCA TGCTCTGCAC 841  
 CCTTCCCTGG GCCTGGCCCT GCTCCCCTCA ACAGTGCGG AAGTGGGTGT ATGAGAGCGG 901  
 40 TGAGTTACGA TTGGGCCCTA TGGCTGCCTT TCTCATTTGA CAGCTCTGTT GGAGTAGGGT 961  
 CTTTGGGCCC ACCAAGAGCA CCACGTTTAG CACAAGATCT TGTACAAGAA TAAATACTTG 1021  
 45 TTTAGTAACC TGAAAAAAAA AAAAAAAGG GCGGCCGCGG AGGCCGAATT CC 1073

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 228 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Gly Ala Trp Ala Met Leu Tyr Gly Val Ser Met Leu Cys Val Leu  
 1 5 10 15  
 Asp Leu Gly Gln Pro Ser Val Val Glu Glu Pro Gly Cys Gly Pro Gly  
 20 25 30  
 Lys Val Gln Asn Gly Ser Gly Asn Asn Thr Arg Cys Cys Ser Leu Tyr  
 35 40 45  
 Ala Pro Gly Lys Glu Asp Cys Pro Lys Glu Arg Cys Ile Cys Val Thr  
 50 55 60

Pro Glu Tyr His Cys Gly Asp Pro Gln Cys Lys Ile Cys Lys His Tyr  
65 70 75 80

5 Pro Cys Gln Pro Gly Gln Arg Val Glu Ser Gln Gly Asp Ile Val Phe  
85 90 95

Gly Phe Arg Cys Val Ala Cys Ala Met Gly Thr Phe Ser Ala Gly Arg  
100 105 110

10 Asp Gly His Cys Arg Leu Trp Thr Asn Cys Ser Gln Phe Gly Phe Leu  
115 120 125

15 Thr Met Phe Pro Gly Asn Lys Thr His Asn Ala Val Cys Ile Pro Glu  
130 135 140

Pro Leu Pro Thr Glu Gln Tyr Gly His Leu Thr Val Ile Phe Leu Val  
145 150 155 160

20 Met Ala Ala Cys Ile Phe Phe Leu Thr Thr Val Gln Leu Gly Leu His  
165 170 175

Ile Trp Gln Leu Arg Arg Gln His Met Cys Pro Arg Glu Thr Gln Pro  
180 185 190

25 Phe Ala Glu Val Gln Leu Ser Ala Glu Asp Ala Cys Ser Phe Gln Phe  
195 200 205

30 Pro Glu Glu Glu Arg Gly Glu Gln Thr Glu Glu Lys Cys His Leu Gly  
210 215 220

Gly Arg Trp Pro  
225

35 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1006 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: cDNA

45 (ix) FEATURE:

- (A) NAME/KEY: CDS  
(B) LOCATION: 1..723

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG GCA CAG CAC GGG GCG ATG GGC GCG TTT CGG GCC CTG TGC GGC CTG  
Met Ala Gln His Gly Ala Met Gly Ala Phe Arg Ala Leu Cys Gly Leu  
1 5 10 15

	GCG CTG CTG TGC GCG CTC AGC CTG GGT CAG CGC CCC ACC GGG GGT CCC	96
	Ala Leu Leu Cys Ala Leu Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro	
	20 25 30	
5	GGG TGC GGC CCT GGG CGC CTC CTG CTT GGG ACG GGA ACG GAC GCG CGC	144
	Gly Cys Gly Pro Gly Arg Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg	
	35 40 45	
10	TGC TGC CGG GTT CAC ACG ACG CGC TGC TGC CGC GAT TAC CCG GGC GAG	192
	Cys Cys Arg Val His Thr Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu	
	50 55 60	
15	GAG TGC TGT TCC GAG TGG GAC TGC ATG TGT GTC CAG CCT GAA TTC CAC	240
	Glu Cys Cys Ser Glu Trp Asp Cys Met Cys Val Gln Pro Glu Phe His	
	65 70 75 80	
20	TGC GGA GAC CCT TGC TGC ACG ACC TGC CGG CAC CAC CCT TGT CCC CCA	288
	Cys Gly Asp Pro Cys Cys Thr Thr Cys Arg His His Pro Cys Pro Pro	
	85 90 95	
25	GGC CAG GGG GTA CAG TCC CAG GGG AAA TTC AGT TTT GGC TTC CAG TGT	336
	Gly Gln Gly Val Gln Ser Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys	
	100 105 110	
30	ATC GAC TGT GCC TCG GGG ACC TTC TCC GGG GGC CAC GAA GGC CAC TGC	384
	Ile Asp Cys Ala Ser Gly Thr Phe Ser Gly Gly His Glu Gly His Cys	
	115 120 125	
35	AAA CCT TGG ACA GAC TGC ACC CAG TTC GGG TTT CTC ACT GTG TTC CCT	432
	Lys Pro Trp Thr Asp Cys Thr Gln Phe Gly Phe Leu Thr Val Phe Pro	
	130 135 140	
40	GGG AAC AAG ACC CAC AAC GCT GTG TGC GTC CCA GGG TCC CCG CCG GCA	480
	Gly Asn Lys Thr His Asn Ala Val Cys Val Pro Gly Ser Pro Pro Ala	
	145 150 155 160	
45	GAG CCG CTT GGG TGG CTG ACC GTC GTC CTC CTG GCC GTG GCC GCC TGC	528
	Glu Pro Leu Gly Trp Leu Thr Val Val Leu Leu Ala Val Ala Ala Cys	
	165 170 175	
50	GTC CTC CTC CTG ACC TCG GCC CAG CTT GGA CTG CAC ATC TGG CAG CTG	576
	Val Leu Leu Leu Thr Ser Ala Gln Leu Gly Leu His Ile Trp Gln Leu	
	180 185 190	
55	AGG AGT CAG TGC ATG TGG CCC CGA GAG ACC CAG CTG CTG CTG GAG GTG	624
	Arg Ser Gln Cys Met Trp Pro Arg Glu Thr Gln Leu Leu Leu Glu Val	
	195 200 205	
50	CCG CCG TCG ACC GAA GAC GCC AGA AGC TGC CAG TTC CCC GAG GAA GAG	672
	Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro Glu Glu Glu	
	210 215 220	
55	CGG GGC GAG CGA TCG GCA GAG GAG AAG GGG CGG CTG GGA GAC CTG TGG	720
	Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly Asp Leu Trp	
	225 230 235 240	



GTG TGAGCCTGGC CGTCCTCCGG GGCCACCGAC CGCAGCCAGC CCCTCCCCAG 773  
Val

5 GAGCTCCCCA GGCCGCAGGG GCTCTGCGTT CTGCTCTGGG CCGGGCCCTG CTCCCCTGGC 833  
AGCAGAAGTG GGTGCAGGAA GGTGGCAGTG ACCAGCGCCC TGGACCATGC AGTTCGGCGG 893  
10 CCGCTCTAAA GGATCCAAGC TTACGTACGC GTGCATGCGA CGTCATAGCT CTTCTATAGT 953  
GTCACCTAAA TTCAATTAC TGGCCGTCGT TTTACAACGT CCTGACTGGG AAA 1006

15 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 241 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

25 Met Ala Gln His Gly Ala Met Gly Ala Phe Arg Ala Leu Cys Gly Leu  
1 5 10 15  
30 Ala Leu Leu Cys Ala Leu Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro  
20 25 30  
Gly Cys Gly Pro Gly Arg Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg  
35 35 40 45  
Cys Cys Arg Val His Thr Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu  
50 55 60  
40 Glu Cys Cys Ser Glu Trp Asp Cys Met Cys Val Gln Pro Glu Phe His  
65 70 75 80  
Cys Gly Asp Pro Cys Cys Thr Thr Cys Arg His His Pro Cys Pro Pro  
85 90 95  
45 Gly Gln Gly Val Gln Ser Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys  
100 105 110  
Ile Asp Cys Ala Ser Gly Thr Phe Ser Gly Gly His Glu Gly His Cys  
115 120 125  
50 Lys Pro Trp Thr Asp Cys Thr Gln Phe Gly Phe Leu Thr Val Phe Pro  
130 135 140  
Gly Asn Lys Thr His Asn Ala Val Cys Val Pro Gly Ser Pro Pro Ala  
145 150 155 160  
55 Glu Pro Leu Gly Trp Leu Thr Val Val Leu Leu Ala Val Ala Ala Cys  
165 170 175

Val Leu Leu Leu Thr Ser Ala Gln Leu Gly Leu His Ile Trp Gln Leu  
180 185 190

Arg Ser Gln Cys Met Trp Pro Arg Glu Thr Gln Leu Leu Leu Glu Val  
195 200 205

Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro Glu Glu Glu  
210 215 220

Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly Asp Leu Trp  
225 230 235 240

Val

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 723 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGGCNCARC AYGGNGCNAT GGGNGCNTTY MGNGCNYTNT GYGGNYTNGC NYTNYTNTGY 60  
GCNYTNWSNY TGGNCARMG NCCNACNGGN GGNCCNGGNT GYGGNCCNGG NMGNYTNYTN 120  
YTNGGNACNG GNACNGAYGC NMGTGYTGY MGNGTNCAYA CNACNMGTG YTG YMGNGAY 180  
TAYCCNGGNG ARGARTGYTG YWSNGARTGG GAYTGYATGT GYGTNCARCC NGARTTYCAY 240  
TGYGGNGAYC CNTGYTGYAC NACNTGYMGN CAYCAYCCNT GYCCNCCNGG NCARGGNGTN 300  
CARWSNCARG GNAARTTYWS NTTYGGNTTY CARTGYATHG AYTGYGCNWS NGGNACNTTY 360  
WSNGGNGGNC AYGARGGNA YTG YAARCCN TGGACNGAYT GYACNCARTT YGGNTTYTNT 420  
ACNGTNTTYC CNGGNAAYAA RACNCAYAAY GCNGTNTGYG TNCCNGGNWS NCCNCCNGCN 480  
GARCCNYTNG GNTGGYTNAC NGTNGTNYTN YTNGCNGTNG CNGCNTGYGT NYTNYTNYTN 540  
ACNWSNGCNC ARYTNGGNYT NCAYATHTGG CARYTNMGNW SNCARTGYAT GTGGCCNMGN 600  
GARACNCARY TNYTNYTNGA RGTNCCNCCN WSNACNGARG AYGCNMGNWS NTGYCARTTY 660  
CCNGARGARG ARMGNGGNGA RMGNWSNGCN GARGARAARG GNMGNYTNGG NGAYYTNTGG 720  
GTN 723

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 228 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Gly Ala Phe Arg Ala Leu Cys Gly Leu Ala Leu Leu Cys Ala Leu  
 1 5 10 15  
 Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro Gly Cys Gly Pro Gly Arg  
 20 25 30  
 Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg Cys Cys Arg Val His Thr  
 35 40 45  
 Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu Glu Cys Cys Ser Glu Trp  
 50 55 60  
 Asp Cys Met Cys Val Gln Pro Glu Phe His Cys Gly Asp Pro Cys Cys  
 65 70 75 80  
 Thr Thr Cys Arg His His Pro Cys Pro Pro Gly Gln Gly Val Gln Ser  
 85 90 95  
 Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys Ile Asp Cys Ala Ser Gly  
 100 105 110  
 Thr Phe Ser Gly Gly His Glu Gly His Cys Lys Pro Trp Thr Asp Cys  
 115 120 125  
 Thr Gln Phe Gly Phe Leu Thr Val Phe Pro Gly Asn Lys Thr His Asn  
 130 135 140  
 Ala Val Cys Val Pro Gly Ser Pro Pro Ala Glu Pro Leu Gly Trp Leu  
 145 150 155 160  
 Thr Val Val Leu Leu Ala Val Ala Ala Cys Val Leu Leu Leu Thr Ser  
 165 170 175  
 Ala Gln Leu Gly Leu His Ile Trp Gln Leu Arg Lys Thr Gln Leu Leu  
 180 185 190  
 Leu Glu Val Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro  
 195 200 205  
 Glu Glu Glu Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly  
 210 215 220  
 Asp Leu Trp Val  
 225

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 232 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Gly Ala Phe Arg Ala Leu Cys Gly Leu Ala Leu Leu Cys Ala Leu  
 1 5 10 15  
 Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro Gly Cys Gly Pro Gly Arg  
 20 25 30  
 Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg Cys Cys Arg Val His Thr  
 35 40 45  
 Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu Glu Cys Cys Ser Glu Trp  
 50 55 60  
 Asp Cys Met Cys Val Gln Pro Glu Phe His Cys Gly Asp Pro Cys Cys  
 65 70 75 80  
 Thr Thr Cys Arg His His Pro Cys Pro Pro Gly Gln Gly Val Gln Ser  
 85 90 95  
 Gln Gly Lys Ser Trp Arg Cys Leu Trp Glu Ser Thr Gln Ala Arg Gly  
 100 105 110  
 Ser Thr Arg Ala Arg Gly Arg Ala Arg Gly His Arg Cys Pro Ala Arg  
 115 120 125  
 Thr Cys Gly Val Trp Gly Pro Glu Ser Cys Glu Ala Gly Gln Ala Arg  
 130 135 140  
 Pro Cys Ser Gly Thr Thr Gly His Glu Ala Leu Gly Val Ser Cys Pro  
 145 150 155 160  
 Cys Phe Leu Ser Leu Gly Phe Ser Ile Gln His Glu Gly Cys Glu Asn  
 165 170 175  
 Pro Ala Gly Arg Trp Gly Arg Val Pro Gly Ala Val Trp Leu Ser Gly  
 180 185 190  
 Pro Gly His Pro Ser Cys Leu Ser Ser Pro His Thr Glu Arg Ala Cys  
 195 200 205  
 Pro Val Pro Pro Gly Val Leu Ser Gly Ala Trp Gly Cys Thr Leu Phe  
 210 215 220  
 Trp Lys Glu Gln Leu Lys Ser Ser  
 225 230

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- 55 (A) LENGTH: 311 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Gly Ala Phe Arg Ala Leu Cys Gly Leu Ala Leu Leu Cys Ala Leu  
 1 5 10 15  
 Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro Gly Cys Gly Pro Gly Arg  
 20 25 30  
 Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg Cys Cys Arg Val His Thr  
 35 40 45  
 Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu Glu Cys Cys Ser Glu Trp  
 50 55 60  
 Asp Cys Met Cys Val Gln Pro Glu Phe His Cys Gly Asp Pro Cys Cys  
 65 70 75 80  
 Thr Thr Cys Arg His His Pro Cys Pro Pro Gly Gln Gly Val Gln Ser  
 85 90 95  
 Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys Ile Asp Cys Ala Ser Gly  
 100 105 110  
 Thr Phe Ser Gly Gly His Glu Gly His Cys Lys Pro Trp Thr Asp Cys  
 115 120 125  
 Thr Gln Phe Gly Phe Leu Thr Val Phe Pro Gly Asn Lys Thr His Asn  
 130 135 140  
 Ala Val Cys Val Pro Gly Ser Pro Pro Ala Glu Pro Leu Gly Trp Leu  
 145 150 155 160  
 Thr Val Val Leu Leu Ala Val Ala Ala Cys Val Leu Leu Leu Thr Ser  
 165 170 175  
 Ala Gln Leu Gly Leu His Ile Trp Gln Leu Arg Ser Gln Cys Met Trp  
 180 185 190  
 Pro Arg Gly Leu Ser Gln Pro Gly Ala Gly Arg Trp Glu His Gly Cys  
 195 200 205  
 Leu Leu Thr Val Ala Pro Leu Gln Arg Pro Ser Cys Cys Trp Arg Cys  
 210 215 220  
 Arg Arg Arg Pro Lys Thr Pro Glu Ala Ala Ser Ser Pro Arg Lys Ser  
 225 230 235 240  
 Gly Ala Ser Asp Arg Gln Arg Arg Arg Gly Gly Trp Glu Thr Cys Gly  
 245 250 255  
 Cys Glu Pro Gly Arg Pro Pro Gly Pro Pro Thr Ala Ala Ser Pro Ser  
 260 265 270

Pro Gly Ala Pro Gln Ala Ala Gly Ala Leu Arg Ser Ala Leu Gly Arg  
275 280 285

5 Ala Leu Leu Pro Trp Gln Gln Lys Trp Val Gln Glu Gly Gly Ser Asp  
290 295 300

10 Gln Arg Pro Gly Pro Cys Ser  
305 310

**For 3 1/2" Disk**

**Pull Tab to Open**



**AVERY™**

**Disk Mailer**

**CONFIDENTIAL**

**PC COMPATIBLE IBM MS/DOS**

Atty. Docket No.: DX0612K1

MAMMALIAN CELL SURFACE

ANTIGENS; RELATED REAGENTS

Daniel M. GORMAN, et al.

USSN: 08/911,423

filed: August 14, 1997

Disk recordation date:

October 31, 1997

**DISK MAILER**

***Handle With Care***

**FIRST CLASS MAIL**

**CONFIDENTIAL**

**PC COMPATIBLE IBM MS/DOS**

Atty. Docket No.: DX0612K1

MAMMALIAN CELL SURFACE

ANTIGENS; RELATED REAGENTS

Daniel M. GORMAN, et al.

USSN: 08/911,423

filed: August 14, 1997

Disk recordation date:

October 31, 1997

## SEQUENCE LISTING

### (1) GENERAL INFORMATION:

- (i) APPLICANT: Gorman, Daniel M.  
Randall, Troy D.  
Zlotnik, Albert
- (ii) TITLE OF INVENTION: MAMMALIAN CELL SURFACE ANTIGENS; RELATED REAGENTS
- (iii) NUMBER OF SEQUENCES: 8
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: DNAX Research Institute
  - (B) STREET: 901 California Avenue
  - (C) CITY: Palo Alto
  - (D) STATE: California
  - (E) COUNTRY: USA
  - (F) ZIP: 94304-1104
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 08/911,423
  - (B) FILING DATE: 14-AUG-1997
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 60/023,419
  - (B) FILING DATE: 16-AUG-1996
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 60/027,901
  - (B) FILING DATE: 07-OCT-1996
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Ching, Edwin P.
  - (B) REGISTRATION NUMBER: 34,090
  - (C) REFERENCE/DOCKET NUMBER: DX0612K
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 650-852-9196
  - (B) TELEFAX: 650-496-1200

### (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1073 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear



(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 68..751

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTCGAGATCC ATTGTGCTGG AAAGGGAACCT CCTGAAATCA GCCGACAGAA GACTCAGGAG	60
AAGCACT ATG GGG GCA TGG GCC ATG CTG TAT GGA GTC TCG ATG CTC TGT	109
Met Gly Ala Trp Ala Met Leu Tyr Gly Val Ser Met Leu Cys	
1 5 10	
GTG CTG GAC CTA GGT CAG CCG AGT GTA GTT GAG GAG CCT GGC TGT GGC	157
Val Leu Asp Leu Gly Gln Pro Ser Val Val Glu Glu Pro Gly Cys Gly	
15 20 25 30	
CCT GGC AAG GTT CAG AAC GGA AGT GGC AAC AAC ACT CGC TGC TGC AGC	205
Pro Gly Lys Val Gln Asn Gly Ser Gly Asn Asn Thr Arg Cys Cys Ser	
35 40 45	
CTG TAT GCT CCA GGC AAG GAG GAC TGT CCA AAA GAA AGG TGC ATA TGT	253
Leu Tyr Ala Pro Gly Lys Glu Asp Cys Pro Lys Glu Arg Cys Ile Cys	
50 55 60	
GTC ACA CCT GAG TAC CAC TGT GGA GAC CCT CAG TGC AAG ATC TGC AAG	301
Val Thr Pro Glu Tyr His Cys Gly Asp Pro Gln Cys Lys Ile Cys Lys	
65 70 75	
CAC TAC CCC TGC CAA CCA GGC CAG AGG GTG GAG TCT CAA GGG GAT ATT	349
His Tyr Pro Cys Gln Pro Gly Gln Arg Val Glu Ser Gln Gly Asp Ile	
80 85 90	
GTG TTT GGC TTC CGG TGT GTT GCC TGT GCC ATG GGC ACC TTC TCC GCA	397
Val Phe Gly Phe Arg Cys Val Ala Cys Ala Met Gly Thr Phe Ser Ala	
95 100 105 110	
GGT CGT GAC GGT CAC TGC AGA CTT TGG ACC AAC TGT TCT CAG TTT GGA	445
Gly Arg Asp Gly His Cys Arg Leu Trp Thr Asn Cys Ser Gln Phe Gly	
115 120 125	
TTT CTC ACC ATG TTC CCT GGG AAC AAG ACC CAC AAT GCT GTG TGC ATC	493
Phe Leu Thr Met Phe Pro Gly Asn Lys Thr His Asn Ala Val Cys Ile	
130 135 140	
CCG GAG CCA CTG CCC ACT GAG CAA TAC GGC CAT TTG ACT GTC ATC TTC	541
Pro Glu Pro Leu Pro Thr Glu Gln Tyr Gly His Leu Thr Val Ile Phe	
145 150 155	
CTG GTC ATG GCT GCA TGC ATT TTC TTC CTA ACC ACA GTC CAG CTC GGC	589
Leu Val Met Ala Ala Cys Ile Phe Phe Leu Thr Thr Val Gln Leu Gly	
160 165 170	
CTG CAC ATA TGG CAG CTG AGG AGG CAA CAC ATG TGT CCC CGA GAG ACC	637

Leu	His	Ile	Trp	Gln	Leu	Arg	Arg	Gln	His	Met	Cys	Pro	Arg	Glu	Thr		
175					180					185					190		
CAG	CCA	TTC	GCG	GAG	GTG	CAG	TTG	TCA	GCT	GAG	GAT	GCT	TGC	AGC	TTC		685
Gln	Pro	Phe	Ala	Glu	Val	Gln	Leu	Ser	Ala	Glu	Asp	Ala	Cys	Ser	Phe		
			195					200					205				
CAG	TTC	CCT	GAG	GAG	GAA	CGC	GGG	GAG	CAG	ACA	GAA	GAA	AAG	TGT	CAT		733
Gln	Phe	Pro	Glu	Glu	Glu	Arg	Gly	Glu	Gln	Thr	Glu	Glu	Lys	Cys	His		
			210				215					220					
CTG	GGG	GGT	CGG	TGG	CCA	AGG	CCT	TGG	TCT	TCT	TCT	TGG	CCCA	AAG			781
Leu	Gly	Gly	Arg	Trp	Pro												
			225														
CAG	ACG	CTAC	AAG	ACT	TGCC	CAG	CTAT	ACC	CTT	GGT	GAGA	GC	AGG	GGCCA	TG	CTCT	GCAC
																	841
CCT	TCC	CTGG	GC	CTGG	CCCT	GCT	CCC	CTCA	AC	AGT	GGCG	AAG	TGG	GTGT	AT	GAG	AGCGG
																	901
TG	AGTT	ACGA	TT	GGG	CCCTA	TGG	CTGC	CTT	TCT	CATT	TGA	CAG	CTCT	GTT	GG	AGT	AGGGT
																	961
CTT	TGG	GGCCC	ACCA	AGAG	CA	CC	ACG	TTTAG	CACA	AGAT	CT	TGT	ACA	AAGAA	TAA	ATA	CTTG
																	1021
TTT	AGT	AACC	TG	AAAA	AAAAA	AAAAA	AGG	GCG	CCG	CGG	AGG	CCGA	ATT	CC			1073

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 228 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Gly	Ala	Trp	Ala	Met	Leu	Tyr	Gly	Val	Ser	Met	Leu	Cys	Val	Leu		
1				5				10					15				
Asp	Leu	Gly	Gln	Pro	Ser	Val	Val	Glu	Glu	Pro	Gly	Cys	Gly	Pro	Gly		
			20					25					30				
Lys	Val	Gln	Asn	Gly	Ser	Gly	Asn	Asn	Thr	Arg	Cys	Cys	Ser	Leu	Tyr		
			35				40					45					
Ala	Pro	Gly	Lys	Glu	Asp	Cys	Pro	Lys	Glu	Arg	Cys	Ile	Cys	Val	Thr		
			50			55					60						
Pro	Glu	Tyr	His	Cys	Gly	Asp	Pro	Gln	Cys	Lys	Ile	Cys	Lys	His	Tyr		
			65		70				75					80			
Pro	Cys	Gln	Pro	Gly	Gln	Arg	Val	Glu	Ser	Gln	Gly	Asp	Ile	Val	Phe		
			85					90						95			
Gly	Phe	Arg	Cys	Val	Ala	Cys	Ala	Met	Gly	Thr	Phe	Ser	Ala	Gly	Arg		
			100					105					110				

Asp Gly His Cys Arg Leu Trp Thr Asn Cys Ser Gln Phe Gly Phe Leu  
 115 120 125  
 Thr Met Phe Pro Gly Asn Lys Thr His Asn Ala Val Cys Ile Pro Glu  
 130 135 140  
 Pro Leu Pro Thr Glu Gln Tyr Gly His Leu Thr Val Ile Phe Leu Val  
 145 150 155 160  
 Met Ala Ala Cys Ile Phe Phe Leu Thr Thr Val Gln Leu Gly Leu His  
 165 170 175  
 Ile Trp Gln Leu Arg Arg Gln His Met Cys Pro Arg Glu Thr Gln Pro  
 180 185 190  
 Phe Ala Glu Val Gln Leu Ser Ala Glu Asp Ala Cys Ser Phe Gln Phe  
 195 200 205  
 Pro Glu Glu Glu Arg Gly Glu Gln Thr Glu Glu Lys Cys His Leu Gly  
 210 215 220  
 Gly Arg Trp Pro  
 225

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1006 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..723

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG GCA CAG CAC GGG GCG ATG GGC GCG TTT CGG GCC CTG TGC GGC CTG	48
Met Ala Gln His Gly Ala Met Gly Ala Phe Arg Ala Leu Cys Gly Leu	
1 5 10 15	
GCG CTG CTG TGC GCG CTC AGC CTG GGT CAG CGC CCC ACC GGG GGT CCC	96
Ala Leu Leu Cys Ala Leu Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro	
20 25 30	
GGG TGC GGC CCT GGG CGC CTC CTG CTT GGG ACG GGA ACG GAC GCG CGC	144
Gly Cys Gly Pro Gly Arg Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg	
35 40 45	
TGC TGC CGG GTT CAC ACG ACG CGC TGC TGC CGC GAT TAC CCG GGC GAG	192
Cys Cys Arg Val His Thr Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu	
50 55 60	

GAG TGC TGT TCC GAG TGG GAC TGC ATG TGT GTC CAG CCT GAA TTC CAC	240
Glu Cys Cys Ser Glu Trp Asp Cys Met Cys Val Gln Pro Glu Phe His	
65 70 75 80	
TGC GGA GAC CCT TGC TGC ACG ACC TGC CGG CAC CAC CCT TGT CCC CCA	288
Cys Gly Asp Pro Cys Cys Thr Thr Cys Arg His His Pro Cys Pro Pro	
85 90 95	
GGC CAG GGG GTA CAG TCC CAG GGG AAA TTC AGT TTT GGC TTC CAG TGT	336
Gly Gln Gly Val Gln Ser Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys	
100 105 110	
ATC GAC TGT GCC TCG GGG ACC TTC TCC GGG GGC CAC GAA GGC CAC TGC	384
Ile Asp Cys Ala Ser Gly Thr Phe Ser Gly Gly His Glu Gly His Cys	
115 120 125	
AAA CCT TGG ACA GAC TGC ACC CAG TTC GGG TTT CTC ACT GTG TTC CCT	432
Lys Pro Trp Thr Asp Cys Thr Gln Phe Gly Phe Leu Thr Val Phe Pro	
130 135 140	
GGG AAC AAG ACC CAC AAC GCT GTG TGC GTC CCA GGG TCC CCG CCG GCA	480
Gly Asn Lys Thr His Asn Ala Val Cys Val Pro Gly Ser Pro Pro Ala	
145 150 155 160	
GAG CCG CTT GGG TGG CTG ACC GTC GTC CTC CTG GCC GTG GCC GCC TGC	528
Glu Pro Leu Gly Trp Leu Thr Val Val Leu Leu Ala Val Ala Ala Cys	
165 170 175	
GTC CTC CTC CTG ACC TCG GCC CAG CTT GGA CTG CAC ATC TGG CAG CTG	576
Val Leu Leu Leu Thr Ser Ala Gln Leu Gly Leu His Ile Trp Gln Leu	
180 185 190	
AGG AGT CAG TGC ATG TGG CCC CGA GAG ACC CAG CTG CTG CTG GAG GTG	624
Arg Ser Gln Cys Met Trp Pro Arg Glu Thr Gln Leu Leu Leu Glu Val	
195 200 205	
CCG CCG TCG ACC GAA GAC GCC AGA AGC TGC CAG TTC CCC GAG GAA GAG	672
Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro Glu Glu Glu	
210 215 220	
CGG GGC GAG CGA TCG GCA GAG GAG AAG GGG CGG CTG GGA GAC CTG TGG	720
Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly Asp Leu Trp	
225 230 235 240	
GTG TGAGCCTGGC CGTCTCCGG GGCACCGAC CGCAGCCAGC CCCTCCCCAG	773
Val	
GAGCTCCCCA GGCCGCAGGG GCTCTGCGTT CTGCTCTGGG CCGGGCCCTG CTCCCCTGGC	833
AGCAGAAGTG GGTGCAGGAA GGTGGCAGTG ACCAGCGCCC TGGACCATGC AGTTCGGCGG	893
CCGCTCTAAA GGATCCAAGC TTACGTACGC GTGCATGCGA CGTCATAGCT CTTCTATAGT	953
GTCACCTAAA TTCAATTAC TGGCCGTCGT TTTACAACGT CCTGACTGGG AAA	1006

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 241 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

[illegible]

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 723 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGGCNCARC AYGGNGCNAT GGGNGCNTTY MGNGCNYTNT GYGGNYTNGC NYTNYTNTGY	60
GCNYTNWSNY TNGGNCARMG NCCNACNGGN GGNCNCGNT GYGGNCCNGG NMGNYTNYTN	120
YTNGGNACNG GNACNGAYGC NMGNTGYTGY MGNGTNCAYA CNACNMGTG YTG YMGNGAY	180
TAYCCNGGNG ARGARTGYTG YWSNGARTGG GAYTGYATGT GYGTNCARCC NGARTTYCAY	240
TGYGGNGAYC CNTGYTGYAC NACNTGYMGN CAYCAYCCNT GYCCNCCNGG NCARGGNGTN	300
CARWSNCARG GNAARTTYWS NTTYGGNTTY CARTGYATHG AYTGYGCNWS NGGNACNTTY	360
WSNGGNGGNC AYGARGGNCA YTG YAARCCN TGGACNGAYT GYACNCARTT YGGNTTYTYN	420
ACNGTNTTYC CNGGNAAYAA RACNCAYAA Y GCNGTNTGYG TNCCNGGNWS NCCNCCNGCN	480
GARCCNYTNG GNTGGYTNAC NGTNGTNYTN YTNGCNGTNG CNGCNTGYGT NYTNYTNYTN	540
ACNWSNGCNC ARYTNGGNYT NCAYATHTGG CARYTNMGNW SNCARTGYAT GTGGCCNMGN	600
GARACNCARY TNYTNYTNGA RGTNCCNCCN WSNACNGARG AYGCNMGNWS NTGYCARTTY	660
CCNGARGARG ARMGNGGNGA RMGNWSNGCN GARGARAARG GNMGNYTNGG NGAYYTNTGG	720
GTN	723

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 228 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met	Gly	Ala	Phe	Arg	Ala	Leu	Cys	Gly	Leu	Ala	Leu	Leu	Cys	Ala	Leu
1				5				10					15		

Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro Gly Cys Gly Pro Gly Arg  
 20 25 30  
 Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg Cys Cys Arg Val His Thr  
 35 40 45  
 Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu Glu Cys Cys Ser Glu Trp  
 50 55 60  
 Asp Cys Met Cys Val Gln Pro Glu Phe His Cys Gly Asp Pro Cys Cys  
 65 70 75 80  
 Thr Thr Cys Arg His His Pro Cys Pro Pro Gly Gln Gly Val Gln Ser  
 85 90 95  
 Gln Gly Lys Phe Ser Phe Gly Phe Gln Cys Ile Asp Cys Ala Ser Gly  
 100 105 110  
 Thr Phe Ser Gly Gly His Glu Gly His Cys Lys Pro Trp Thr Asp Cys  
 115 120 125  
 Thr Gln Phe Gly Phe Leu Thr Val Phe Pro Gly Asn Lys Thr His Asn  
 130 135 140  
 Ala Val Cys Val Pro Gly Ser Pro Pro Ala Glu Pro Leu Gly Trp Leu  
 145 150 155 160  
 Thr Val Val Leu Leu Ala Val Ala Ala Cys Val Leu Leu Leu Thr Ser  
 165 170 175  
 Ala Gln Leu Gly Leu His Ile Trp Gln Leu Arg Lys Thr Gln Leu Leu  
 180 185 190  
 Leu Glu Val Pro Pro Ser Thr Glu Asp Ala Arg Ser Cys Gln Phe Pro  
 195 200 205  
 Glu Glu Glu Arg Gly Glu Arg Ser Ala Glu Glu Lys Gly Arg Leu Gly  
 210 215 220  
 Asp Leu Trp Val  
 225

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 232 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Gly Ala Phe Arg Ala Leu Cys Gly Leu Ala Leu Leu Cys Ala Leu  
 1 5 10 15  
 Ser Leu Gly Gln Arg Pro Thr Gly Gly Pro Gly Cys Gly Pro Gly Arg  
 20 25 30  
 Leu Leu Leu Gly Thr Gly Thr Asp Ala Arg Cys Cys Arg Val His Thr  
 35 40 45  
 Thr Arg Cys Cys Arg Asp Tyr Pro Gly Glu Glu Cys Cys Ser Glu Trp  
 50 55 60  
 Asp Cys Met Cys Val Gln Pro Glu Phe His Cys Gly Asp Pro Cys Cys  
 65 70 75 80  
 Thr Thr Cys Arg His His Pro Cys Pro Pro Gly Gln Gly Val Gln Ser  
 85 90 95  
 Gln Gly Lys Ser Trp Arg Cys Leu Trp Glu Ser Thr Gln Ala Arg Gly  
 100 105 110  
 Ser Thr Arg Ala Arg Gly Arg Ala Arg Gly His Arg Cys Pro Ala Arg  
 115 120 125  
 Thr Cys Gly Val Trp Gly Pro Glu Ser Cys Glu Ala Gly Gln Ala Arg  
 130 135 140  
 Pro Cys Ser Gly Thr Thr Gly His Glu Ala Leu Gly Val Ser Cys Pro  
 145 150 155 160  
 Cys Phe Leu Ser Leu Gly Phe Ser Ile Gln His Glu Gly Cys Glu Asn  
 165 170 175  
 Pro Ala Gly Arg Trp Gly Arg Val Pro Gly Ala Val Trp Leu Ser Gly  
 180 185 190  
 Pro Gly His Pro Ser Cys Leu Ser Ser Pro His Thr Glu Arg Ala Cys  
 195 200 205  
 Pro Val Pro Pro Gly Val Leu Ser Gly Ala Trp Gly Cys Thr Leu Phe  
 210 215 220  
 Trp Lys Glu Gln Leu Lys Ser Ser  
 225 230

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 311 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met	Gly	Ala	Phe	Arg	Ala	Leu	Cys	Gly	Leu	Ala	Leu	Leu	Cys	Ala	Leu	
1				5					10					15		
Ser	Leu	Gly	Gln	Arg	Pro	Thr	Gly	Gly	Pro	Gly	Cys	Gly	Pro	Gly	Arg	
			20					25					30			
Leu	Leu	Leu	Gly	Thr	Gly	Thr	Asp	Ala	Arg	Cys	Cys	Arg	Val	His	Thr	
		35					40					45				
Thr	Arg	Cys	Cys	Arg	Asp	Tyr	Pro	Gly	Glu	Glu	Cys	Cys	Ser	Glu	Trp	
	50					55					60					
Asp	Cys	Met	Cys	Val	Gln	Pro	Glu	Phe	His	Cys	Gly	Asp	Pro	Cys	Cys	
65					70					75					80	
Thr	Thr	Cys	Arg	His	His	Pro	Cys	Pro	Pro	Gly	Gln	Gly	Val	Gln	Ser	
				85					90					95		
Gln	Gly	Lys	Phe	Ser	Phe	Gly	Phe	Gln	Cys	Ile	Asp	Cys	Ala	Ser	Gly	
			100					105					110			
Thr	Phe	Ser	Gly	Gly	His	Glu	Gly	His	Cys	Lys	Pro	Trp	Thr	Asp	Cys	
		115					120					125				
Thr	Gln	Phe	Gly	Phe	Leu	Thr	Val	Phe	Pro	Gly	Asn	Lys	Thr	His	Asn	
	130					135					140					
Ala	Val	Cys	Val	Pro	Gly	Ser	Pro	Pro	Ala	Glu	Pro	Leu	Gly	Trp	Leu	
145					150					155					160	
Thr	Val	Val	Leu	Leu	Ala	Val	Ala	Ala	Cys	Val	Leu	Leu	Leu	Thr	Ser	
			165						170					175		
Ala	Gln	Leu	Gly	Leu	His	Ile	Trp	Gln	Leu	Arg	Ser	Gln	Cys	Met	Trp	
		180						185					190			
Pro	Arg	Gly	Leu	Ser	Gln	Pro	Gly	Ala	Gly	Arg	Trp	Glu	His	Gly	Cys	
		195					200					205				
Leu	Leu	Thr	Val	Ala	Pro	Leu	Gln	Arg	Pro	Ser	Cys	Cys	Trp	Arg	Cys	
	210					215					220					
Arg	Arg	Arg	Pro	Lys	Thr	Pro	Glu	Ala	Ala	Ser	Ser	Pro	Arg	Lys	Ser	
225					230					235					240	
Gly	Ala	Ser	Asp	Arg	Gln	Arg	Arg	Arg	Gly	Gly	Trp	Glu	Thr	Cys	Gly	
			245						250					255		
Cys	Glu	Pro	Gly	Arg	Pro	Pro	Gly	Pro	Pro	Thr	Ala	Ala	Ser	Pro	Ser	
		260					265						270			
Pro	Gly	Ala	Pro	Gln	Ala	Ala	Gly	Ala	Leu	Arg	Ser	Ala	Leu	Gly	Arg	
	275						280					285				
Ala	Leu	Leu	Pro	Trp	Gln	Gln	Lys	Trp	Val	Gln	Glu	Gly	Gly	Ser	Asp	
	290					295					300					

Gln Arg Pro Gly Pro Cys Ser  
305 310

gln arg pro gly pro cys ser  
305 310